CN115215821A - 木脂素衍生物、其制备方法及用途 - Google Patents
木脂素衍生物、其制备方法及用途 Download PDFInfo
- Publication number
- CN115215821A CN115215821A CN202110419576.1A CN202110419576A CN115215821A CN 115215821 A CN115215821 A CN 115215821A CN 202110419576 A CN202110419576 A CN 202110419576A CN 115215821 A CN115215821 A CN 115215821A
- Authority
- CN
- China
- Prior art keywords
- compound
- hydrogen
- halogen
- group
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 229930013686 lignan Natural products 0.000 title abstract description 7
- 235000009408 lignans Nutrition 0.000 title abstract description 7
- 150000005692 lignans Chemical class 0.000 title abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 36
- 201000010099 disease Diseases 0.000 claims abstract description 35
- 230000000694 effects Effects 0.000 claims abstract description 31
- 230000008811 mitochondrial respiratory chain Effects 0.000 claims abstract description 20
- 230000001965 increasing effect Effects 0.000 claims abstract description 11
- 239000003112 inhibitor Substances 0.000 claims abstract description 10
- 125000001424 substituent group Chemical group 0.000 claims abstract description 10
- 230000006705 mitochondrial oxidative phosphorylation Effects 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 147
- 229910052739 hydrogen Inorganic materials 0.000 claims description 40
- 239000001257 hydrogen Substances 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 36
- 229910052736 halogen Inorganic materials 0.000 claims description 32
- 150000002367 halogens Chemical class 0.000 claims description 32
- -1 Alkyl radical Chemical class 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 18
- 201000008482 osteoarthritis Diseases 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 150000002431 hydrogen Chemical group 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 12
- 230000032677 cell aging Effects 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 230000004770 neurodegeneration Effects 0.000 claims description 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 8
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 7
- 125000001188 haloalkyl group Chemical group 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 5
- 125000004104 aryloxy group Chemical group 0.000 claims description 5
- 208000019423 liver disease Diseases 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 230000010094 cellular senescence Effects 0.000 claims description 4
- 208000020832 chronic kidney disease Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000002516 radical scavenger Substances 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- 208000002177 Cataract Diseases 0.000 claims description 3
- 208000019693 Lung disease Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 150000004820 halides Chemical class 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 208000001076 sarcopenia Diseases 0.000 claims description 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 150000005840 aryl radicals Chemical class 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000003176 fibrotic effect Effects 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 3
- 229910052740 iodine Inorganic materials 0.000 abstract description 3
- 230000002407 ATP formation Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 75
- 210000004027 cell Anatomy 0.000 description 56
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 54
- 241000699666 Mus <mouse, genus> Species 0.000 description 50
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 42
- 239000000243 solution Substances 0.000 description 36
- 238000011156 evaluation Methods 0.000 description 34
- 210000001519 tissue Anatomy 0.000 description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 230000015572 biosynthetic process Effects 0.000 description 30
- 238000003786 synthesis reaction Methods 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 238000002474 experimental method Methods 0.000 description 27
- 230000002829 reductive effect Effects 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 238000000034 method Methods 0.000 description 21
- 238000003756 stirring Methods 0.000 description 21
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 19
- 238000010898 silica gel chromatography Methods 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- 210000004072 lung Anatomy 0.000 description 17
- 238000010186 staining Methods 0.000 description 17
- NQWVSMVXKMHKTF-JKSUJKDBSA-N (-)-Arctigenin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-JKSUJKDBSA-N 0.000 description 16
- 208000024827 Alzheimer disease Diseases 0.000 description 16
- YYGRXNOXOVZIKE-UHFFFAOYSA-N Arctigenin Natural products COC1CCC(CC2COC(=O)C2CC3CCC(O)C(C3)OC)CC1OC YYGRXNOXOVZIKE-UHFFFAOYSA-N 0.000 description 16
- OIFFJDGSLVHPCW-UHFFFAOYSA-N Guayarol Natural products COc1ccc(CC2C(Cc3ccc(O)c(O)c3)COC2=O)cc1OC OIFFJDGSLVHPCW-UHFFFAOYSA-N 0.000 description 16
- NQWVSMVXKMHKTF-UHFFFAOYSA-N L-Arctigenin Natural products C1=C(OC)C(OC)=CC=C1CC1C(CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-UHFFFAOYSA-N 0.000 description 16
- 238000005481 NMR spectroscopy Methods 0.000 description 16
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 16
- NWFYESYCEQICQP-UHFFFAOYSA-N methylmatairesinol Natural products C1=C(OC)C(OC)=CC=C1CC1C(=O)OCC1CC1=CC=C(O)C(OC)=C1 NWFYESYCEQICQP-UHFFFAOYSA-N 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 15
- 238000001914 filtration Methods 0.000 description 14
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 14
- 238000011830 transgenic mouse model Methods 0.000 description 14
- 241000699660 Mus musculus Species 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000032683 aging Effects 0.000 description 11
- 210000001072 colon Anatomy 0.000 description 11
- 230000009758 senescence Effects 0.000 description 11
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 10
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 10
- 239000003208 petroleum Substances 0.000 description 10
- 229910001868 water Inorganic materials 0.000 description 10
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 9
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 9
- 229960002591 hydroxyproline Drugs 0.000 description 9
- 210000000629 knee joint Anatomy 0.000 description 9
- 210000005228 liver tissue Anatomy 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 230000009261 transgenic effect Effects 0.000 description 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 7
- 229910052794 bromium Inorganic materials 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 229910052801 chlorine Inorganic materials 0.000 description 7
- 229910052731 fluorine Inorganic materials 0.000 description 7
- 239000011737 fluorine Substances 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 6
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 6
- 206010019668 Hepatic fibrosis Diseases 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- MHSVUSZEHNVFKW-UHFFFAOYSA-N bis-4-nitrophenyl phosphate Chemical compound C=1C=C([N+]([O-])=O)C=CC=1OP(=O)(O)OC1=CC=C([N+]([O-])=O)C=C1 MHSVUSZEHNVFKW-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000010791 quenching Methods 0.000 description 6
- 230000000171 quenching effect Effects 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- 208000004232 Enteritis Diseases 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 208000019425 cirrhosis of liver Diseases 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 5
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 208000005069 pulmonary fibrosis Diseases 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 238000010175 APPswe/PSEN1dE9 Methods 0.000 description 4
- UKQCHMIPIOBRDN-CYBMUJFWSA-N CC(C)(C)OC(C[C@@H](CC(C=C1)=CC(OC)=C1OC)CO)=O Chemical compound CC(C)(C)OC(C[C@@H](CC(C=C1)=CC(OC)=C1OC)CO)=O UKQCHMIPIOBRDN-CYBMUJFWSA-N 0.000 description 4
- JVXAIYDNESZSEB-JKSUJKDBSA-N CNC(C=C(C[C@H]([C@@H](CC(C=C1)=CC(OC)=C1OC)CO1)C1=O)C=C1)=C1O Chemical compound CNC(C=C(C[C@H]([C@@H](CC(C=C1)=CC(OC)=C1OC)CO1)C1=O)C=C1)=C1O JVXAIYDNESZSEB-JKSUJKDBSA-N 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 229940009456 adriamycin Drugs 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000009266 disease activity Effects 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 210000003041 ligament Anatomy 0.000 description 4
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000005499 meniscus Effects 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 4
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- XOLCTMMTFHXLNE-XZOQPEGZSA-N (3R,4R)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(3-methoxy-4-phenylmethoxyphenyl)methyl]oxolan-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(OCC=3C=CC=CC=3)=CC=2)C(=O)OC1 XOLCTMMTFHXLNE-XZOQPEGZSA-N 0.000 description 3
- PZTPLHNGSCAOID-FCHUYYIVSA-N (3r,4r)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(3-hydroxy-4-phenylmethoxyphenyl)methyl]oxolan-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(O)C(OCC=3C=CC=CC=3)=CC=2)C(=O)OC1 PZTPLHNGSCAOID-FCHUYYIVSA-N 0.000 description 3
- RNZYEJXSPRJDKA-KRWDZBQOSA-N (4S)-4-benzyl-3-[3-(3,4-dimethoxyphenyl)propanoyl]-1,3-oxazolidin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1CCC(=O)N1C(=O)OC[C@@H]1CC1=CC=CC=C1 RNZYEJXSPRJDKA-KRWDZBQOSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 108010006654 Bleomycin Proteins 0.000 description 3
- VGXGRYVAJOENGZ-SNVBAGLBSA-N C1=C(OC)C(OC)=CC=C1C[C@@H]1OC(=O)CC1 Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1OC(=O)CC1 VGXGRYVAJOENGZ-SNVBAGLBSA-N 0.000 description 3
- USANUFLDQDCAHA-UHFFFAOYSA-N CC(C)(C)OC(CC(CC(C=C1)=CC(OC)=C1OC)C=O)=O Chemical compound CC(C)(C)OC(CC(CC(C=C1)=CC(OC)=C1OC)C=O)=O USANUFLDQDCAHA-UHFFFAOYSA-N 0.000 description 3
- PZJNSRUASYDULO-FCHUYYIVSA-N COC(C=CC(C[C@@H](CO1)[C@@H](CC(C=C2)=CC(N)=C2OCC2=CC=CC=C2)C1=O)=C1)=C1OC Chemical compound COC(C=CC(C[C@@H](CO1)[C@@H](CC(C=C2)=CC(N)=C2OCC2=CC=CC=C2)C1=O)=C1)=C1OC PZJNSRUASYDULO-FCHUYYIVSA-N 0.000 description 3
- YNIXGHKSOLRHIB-FCHUYYIVSA-N COC(C=CC(C[C@@H](CO1)[C@@H](CC(C=C2)=CC([N+]([O-])=O)=C2OCC2=CC=CC=C2)C1=O)=C1)=C1OC Chemical compound COC(C=CC(C[C@@H](CO1)[C@@H](CC(C=C2)=CC([N+]([O-])=O)=C2OCC2=CC=CC=C2)C1=O)=C1)=C1OC YNIXGHKSOLRHIB-FCHUYYIVSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000001188 articular cartilage Anatomy 0.000 description 3
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 3
- 229940073608 benzyl chloride Drugs 0.000 description 3
- 229960001561 bleomycin Drugs 0.000 description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- YEJRWHAVMIAJKC-UHFFFAOYSA-N gamma-butyrolactone Natural products O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 3
- 230000034659 glycolysis Effects 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 3
- 229950004847 navitoclax Drugs 0.000 description 3
- 235000006408 oxalic acid Nutrition 0.000 description 3
- 230000008533 pain sensitivity Effects 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- OJOFMLDBXPDXLQ-VIFPVBQESA-N (4s)-4-benzyl-1,3-oxazolidin-2-one Chemical compound C1OC(=O)N[C@H]1CC1=CC=CC=C1 OJOFMLDBXPDXLQ-VIFPVBQESA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- KWOMNGWHOBWKBP-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)propanoic acid Chemical compound COC1=CC=C(C(C)C(O)=O)C=C1OC KWOMNGWHOBWKBP-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 2
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- JSPMCNDUVPOYKD-UHFFFAOYSA-N CC(C(CC(C=C1)=CC(OC)=C1OC)C1CC(C=C2)=CC(OC)=C2OCC2=CC=CC=C2)OC1=O Chemical compound CC(C(CC(C=C1)=CC(OC)=C1OC)C1CC(C=C2)=CC(OC)=C2OCC2=CC=CC=C2)OC1=O JSPMCNDUVPOYKD-UHFFFAOYSA-N 0.000 description 2
- UNIGXZVZVJZPSP-XZOQPEGZSA-N COC(C=CC(C[C@@H](CO1)[C@@H](CC(C=C2)=CC(OCCC3=CC=CC=C3)=C2O)C1=O)=C1)=C1OC Chemical compound COC(C=CC(C[C@@H](CO1)[C@@H](CC(C=C2)=CC(OCCC3=CC=CC=C3)=C2O)C1=O)=C1)=C1OC UNIGXZVZVJZPSP-XZOQPEGZSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 238000012347 Morris Water Maze Methods 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 229930188620 butyrolactone Natural products 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 2
- 229910052808 lithium carbonate Inorganic materials 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 230000006540 mitochondrial respiration Effects 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000010627 oxidative phosphorylation Effects 0.000 description 2
- 108700042657 p16 Genes Proteins 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 210000004417 patella Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 201000002793 renal fibrosis Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035806 respiratory chain Effects 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- XOSXWYQMOYSSKB-LDKJGXKFSA-L water blue Chemical compound CC1=CC(/C(\C(C=C2)=CC=C2NC(C=C2)=CC=C2S([O-])(=O)=O)=C(\C=C2)/C=C/C\2=N\C(C=C2)=CC=C2S([O-])(=O)=O)=CC(S(O)(=O)=O)=C1N.[Na+].[Na+] XOSXWYQMOYSSKB-LDKJGXKFSA-L 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- OSTBLDHANBUNQO-UHFFFAOYSA-N (3-nitro-4-phenylmethoxyphenyl)methanol Chemical compound [O-][N+](=O)C1=CC(CO)=CC=C1OCC1=CC=CC=C1 OSTBLDHANBUNQO-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- QJVMPBMNXBEMTE-UHFFFAOYSA-N 3-[tert-butyl(dimethyl)silyl]oxy-4-phenylmethoxybenzaldehyde Chemical compound CC(C)(C)[Si](C)(C)OC1=CC(C=O)=CC=C1OCC1=CC=CC=C1 QJVMPBMNXBEMTE-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- HUNGEAFDVLSPAM-UHFFFAOYSA-N 3-hydroxy-4-phenylmethoxybenzaldehyde Chemical compound OC1=CC(C=O)=CC=C1OCC1=CC=CC=C1 HUNGEAFDVLSPAM-UHFFFAOYSA-N 0.000 description 1
- COPBKCYMXSUALT-UHFFFAOYSA-N 3h-1,3-oxazol-2-one Chemical compound O=C1NC=CO1.O=C1NC=CO1 COPBKCYMXSUALT-UHFFFAOYSA-N 0.000 description 1
- KWOSNEXLSCVFGC-UHFFFAOYSA-N 4-(bromomethyl)-2-nitro-1-phenylmethoxybenzene Chemical compound [O-][N+](=O)C1=CC(CBr)=CC=C1OCC1=CC=CC=C1 KWOSNEXLSCVFGC-UHFFFAOYSA-N 0.000 description 1
- AXDJCCTWPBKUKL-UHFFFAOYSA-N 4-[(4-aminophenyl)-(4-imino-3-methylcyclohexa-2,5-dien-1-ylidene)methyl]aniline;hydron;chloride Chemical compound Cl.C1=CC(=N)C(C)=CC1=C(C=1C=CC(N)=CC=1)C1=CC=C(N)C=C1 AXDJCCTWPBKUKL-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- OJOFMLDBXPDXLQ-UHFFFAOYSA-N 4-benzyl-1,3-oxazolidin-2-one Chemical compound C1OC(=O)NC1CC1=CC=CC=C1 OJOFMLDBXPDXLQ-UHFFFAOYSA-N 0.000 description 1
- HWJWNWZJUYCGKV-UHFFFAOYSA-N 5-[5-methyl-1-[[3-(4-methylsulfonylpiperidin-1-yl)phenyl]methyl]-1,2,4-triazol-3-yl]-3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazole Chemical compound CC1=NC(C=2ON=C(N=2)C=2C=CC(OC(F)(F)F)=CC=2)=NN1CC(C=1)=CC=CC=1N1CCC(S(C)(=O)=O)CC1 HWJWNWZJUYCGKV-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000012664 BCL-2-inhibitor Substances 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- XTKGNYPOCJJMQV-UHFFFAOYSA-N CC(C(CC(C=C1)=CC(OC)=C1OC)C1)OC1=O Chemical compound CC(C(CC(C=C1)=CC(OC)=C1OC)C1)OC1=O XTKGNYPOCJJMQV-UHFFFAOYSA-N 0.000 description 1
- NZYXLTKPBXVUBQ-UHFFFAOYSA-N CC(C(CC(C=C1)=CC(OC)=C1OC)C1CC(C=C2)=CC(OC)=C2O)OC1=O Chemical compound CC(C(CC(C=C1)=CC(OC)=C1OC)C1CC(C=C2)=CC(OC)=C2O)OC1=O NZYXLTKPBXVUBQ-UHFFFAOYSA-N 0.000 description 1
- HTWWXUKDNWWSQY-UHFFFAOYSA-N CC(C(CC(OC(C)(C)C)=O)CC(C=C1)=CC(OC)=C1OC)O Chemical compound CC(C(CC(OC(C)(C)C)=O)CC(C=C1)=CC(OC)=C1OC)O HTWWXUKDNWWSQY-UHFFFAOYSA-N 0.000 description 1
- UBQSWWGDEGBKLT-XZWHSSHBSA-N COC(C=CC(C[C@@H](CO1)[C@@H](CC(C=C2)=CC(OCCC3=CC=CC=C3)=C2OCC2=CC=CC=C2)C1=O)=C1)=C1OC Chemical compound COC(C=CC(C[C@@H](CO1)[C@@H](CC(C=C2)=CC(OCCC3=CC=CC=C3)=C2OCC2=CC=CC=C2)C1=O)=C1)=C1OC UBQSWWGDEGBKLT-XZWHSSHBSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 1
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 102000002023 NADH:ubiquinone oxidoreductases Human genes 0.000 description 1
- 108050009313 NADH:ubiquinone oxidoreductases Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010057178 Osteoarthropathies Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000012412 Presenilin-1 Human genes 0.000 description 1
- 108010036933 Presenilin-1 Proteins 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- OYVWEXAZMRHNBY-UHFFFAOYSA-N [3-[tert-butyl(dimethyl)silyl]oxy-4-phenylmethoxyphenyl]methanol Chemical compound CC(C)(C)[Si](C)(C)OC1=CC(CO)=CC=C1OCC1=CC=CC=C1 OYVWEXAZMRHNBY-UHFFFAOYSA-N 0.000 description 1
- TZZKFMCUHMSFKK-UHFFFAOYSA-N [5-(bromomethyl)-2-phenylmethoxyphenoxy]-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OC1=CC(CBr)=CC=C1OCC1=CC=CC=C1 TZZKFMCUHMSFKK-UHFFFAOYSA-N 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000007171 acid catalysis Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000000816 effect on animals Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 150000003947 ethylamines Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- YPGCWEMNNLXISK-UHFFFAOYSA-N hydratropic acid Chemical class OC(=O)C(C)C1=CC=CC=C1 YPGCWEMNNLXISK-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical group 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- MIJSBCQXHMDVBQ-UHFFFAOYSA-N methyl 3-nitro-4-phenylmethoxybenzoate Chemical compound [O-][N+](=O)C1=CC(C(=O)OC)=CC=C1OCC1=CC=CC=C1 MIJSBCQXHMDVBQ-UHFFFAOYSA-N 0.000 description 1
- 150000003956 methylamines Chemical class 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000012335 pathological evaluation Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 208000030087 premature aging syndrome Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000003375 selectivity assay Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 230000006886 spatial memory Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009092 tissue dysfunction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种木脂素衍生物、其制备方法及用途,所述木脂素衍生物结构如式I所示,式中,各取代基的定义如说明书和权利要求书中所述。本发明的木脂素衍生物,能够作为线粒体呼吸链复合物I抑制剂,抑制线粒体的氧化磷酸化作用及ATP的生成,用于预防和/或治疗与线粒体呼吸链复合物I活性或表达升高、或者线粒体氧化磷酸化作用增强相关的疾病。
Description
技术领域
本发明涉及药物化学领域,具体地,本发明涉及木脂素类衍生物及其作为线粒体呼吸链复合物I抑制剂的用途。
背景技术
线粒体呼吸链复合物I(NADH:泛醌氧化还原酶)位于线粒体的内膜,是氧化磷酸化(oxidative phosphorylation;OXPHOS)呼吸链中最重要的蛋白复合体之一,可以将电子从烟酰胺腺嘌呤二核苷酸(Nicotinamide Adenine Dinucleotide,NADH)传递至辅酶Q(CoQ),同时偶联四个质子从线粒体基质泵出至膜间隙,形成跨膜质子梯度,驱动腺嘌呤核苷三磷酸(ATP)的合成。复合物I泵出的质子占整个呼吸链的40%左右。通过复合物I进行的电子传递及偶联的质子泵出是正常细胞中能量产生的主要途径。
与正常细胞不同,肿瘤细胞通常更依赖于糖酵解途径进行能量供应,而非线粒体呼吸OXPHOS途径。不过近年的研发发现,在肿瘤的发生过程和肿瘤细胞的转化过程中,能量代谢方式是在不断变化的,有部分肿瘤由于糖酵解相关基因的突变而将能量供应方式转向OXPHOS。肿瘤细胞能量代谢的改变为肿瘤的治疗提供了新思路,抑制这类肿瘤中的OXPHOS过程成为一条独特的治疗途径。美国德州大学安德森癌症中心研究人员开发了一系列高效线粒体呼吸链复合体I抑制剂,体外模型中能有效地抑制急性白血病细胞系的生长,其中药动学性质和口服生物利用度表现良好的IACS-10759目前正处于急性髓性白血病以及实体瘤和淋巴瘤的I期临床试验中(Nature Medicine,2018,24,1036-1046)。此外,新的研究表明,依靠糖酵解代谢途径的肿瘤细胞在一些“靶向疗法”后发生的治疗抗性可通过代谢重组至OXPHOS依赖性的转变来实现,而OXPHOS抑制剂能有效地靶向发生代谢性重组耐药肿瘤细胞。例如,线粒体呼吸链复合物I抑制剂二甲双胍能有效地杀死5-氟尿嘧啶耐药的结肠癌细胞。(Oncotarget.2015Dec 8;6(39):41706-21.)。
除了抑制OXPHOS代谢途径的能量供应,线粒体呼吸链复合体I抑制剂还通过更广泛的机制发挥抗肿瘤作用,例如增加细胞内活性氧簇(ROS)的蓄积导致细胞毒性、抑制厌氧诱导因子1型alpha(HIF-1α)信号、干扰线粒体膜电位、激活AMP-活化的蛋白激酶(AMPK)等。可见,线粒体呼吸链复合体I抑制剂还可能用作广谱的抗肿瘤药物或者与其他机制的抗肿瘤药物联用。
另一方面,研究表明,许多与年龄有关的疾病都与细胞衰老有关,包括早衰综合征、心血管疾病、骨关节炎、癌症、神经退行性疾病、慢性肾病、慢性阻塞性肺病、特发性肺纤维化以及II型糖尿病、皮肤衰老、色斑沉积等病变。衰老细胞是一类细胞周期永久停滞、却保持着高代谢活性、并持续释放衰老相关分泌表型(SASP)的细胞。衰老细胞在衰老过程中被动地积聚在器官中,导致组织功能障碍。正常组织的“磨损”过程产生的初级衰老细胞会诱导临近细胞发生衰老,使更多衰老细胞在病灶部位产生,使组织中具有增殖能力的细胞缺失,从而导致疾病的发生。例如胰岛β细胞的缺失会导致糖尿病,肺上皮细胞的缺失会导致肺纤维化。同时,衰老细胞分泌的SASP引起的炎症也会引起疾病,如动脉粥样硬化、心肌梗塞、心肌细胞肥大等心血管病变以及慢性阻塞性肺病等肺部病变。另外,SASP介导的细胞外基质重塑也可在组织纤维化进程中起促进作用,如肺纤维化、肝纤维化和肾纤维化等。衰老细胞普遍存在于众多类型的肝病组织中,包括病毒性肝炎、酒精性肝病、非酒精性脂肪肝、肝纤维化、肝硬化以及肝细胞癌。衰老的肝细胞、星形细胞和免疫细胞可通过SASP、代谢功能、免疫反应等途径促进肝病进展。同样,衰老细胞也存在于食道、胃、胆管、胰腺、肠道等其他消化器官中,在胆管炎、炎症性肠病、消化道肿瘤等病变发生发展过程中起到了重要作用。衰老是神经退行性疾病的主要风险因素,包括阿尔兹海默症、帕金森症在内的多种神经退行性疾病的形成与细胞衰老有关。衰老细胞通过引起神经炎症、增加氧化应力、破化神经元功能、阻碍神经系统再生等方式推动神经退行性疾病的形成和发展。衰老细胞清除剂是一类能选择性清除衰老细胞的化合物,能延长健康寿命,使个体在老龄化过程中减少慢性疾病困扰,包括减少肿瘤发生、延长中位生存期,减轻动脉粥样硬化、骨关节炎、白内障、黄斑变性、心肌肥大、慢性肾病、慢性肝病、肺纤维化、神经退行性疾病、脂肪代谢紊乱和肌肉减少症等老龄化改变。多个衰老细胞清除剂对衰老相关疾病治疗作用进入临床研究,如达沙替尼和槲皮素的组合物治疗特发性肺纤维化进入I期临床研究,UBX0101治疗骨关节炎进入II期临床(Ageing Research Reviews,2020,66:101251.)。
除了一些亚群肿瘤细胞的OXPHOS增强以外,研究表明衰老细胞的OXPHOS过程同样增强。为了维持高水平的分泌表型,衰老细胞必须做出显著的代谢改变,比如耗氧量和能量生成增加,脂质分解更加活跃,同时产生高水平的ROS。相比于糖酵解,衰老细胞更加依赖于线粒体的OXPHOS作用提供能量,线粒体功能的增强是衰老细胞分泌SASP的一个重要决定因素。因此在理论上,靶向线粒体呼吸链复合物I、阻断OXPHOS是一种清除衰老细胞来的合理方法。有研究表明,线粒体靶向的他莫昔芬可以通过抑制线粒体呼吸链复合物I和降低线粒体膜电位而选择性地清除衰老细胞(Cell Death&Differentiation,2018,26(2),276-290.)。所以,应用线粒体呼吸链复合物I抑制剂来预防或治疗细胞衰老相关疾病或许是一种行之有效的方法。
文献报道(ACS Chemical Biology,2013,8(1),257–267.),天然产物牛蒡子苷元(Arctigenin)是线粒体呼吸链复合物I的一个中等强度的选择性抑制剂。牛蒡子苷元具有抗炎、抗感染、抗代谢紊乱、抗神经损伤等药理作用,对于治疗癌症和动脉粥样硬化、糖尿病、阿尔兹海默症等衰老相关疾病具有很好的效果。但是它口服后易代谢,药代动力学性质差,生物利用率很低,限制了其作为口服药物的应用(Acta Pharmacologica Sinica,2018,39,787–801.)。
发明内容
本发明的目的在于提供一种对牛蒡子苷元进行结构改造所得的木脂素类衍生物,能够有效地抑制线粒体呼吸链复合物I。
本发明的第一方面,提供一种式I所示的化合物、其对映异构体、非对应异构体、外消旋混合物、氘代化物及药学上可接受的盐,
其中,Rx选自氢、羟基、卤素;
R0选自氢、卤素、C1-C6烷基、羟基取代的C1-C6烷基、C1-C6卤代烷基;
R1选自卤素、C1-C6卤代烷基、-N(R5)2、C1-C6烷氧基、C1-C6氘代烷氧基或-O-L-G;其中,L为C1-6亚烷基,所述亚烷基的氢原子任选地以化学键允许的方式和数量被卤素、羟基、=O所取代;G为卤素、C1-C6卤代烷基、-CN、-N(R9)2、-COOR10、-P+(R11)3Y-、-N+(R11)3Y-、C6-10芳基、C6-10芳氧基、4-8元杂环基或5-10元杂芳基;所述芳基、芳氧基、杂环基和杂芳基未被取代或被1、2、3或4个选自下组的基团所取代:卤素、羟基、-N(R12)2、硝基、氰基、C1-C6烷基、C1-C6卤代烷基、C1-C6烷氧基、4-8元杂环基;
R2和R3各自独立地为C1-C6烷基、C1-C6卤代烷基,或R2和R3连接起来并连同相连接的C形成未取代或取代的5-8元杂环基,所述取代是指被选自下组的一个或多个取代基取代:卤素、C1-C6烷基;
R4为氢或C1-C6烷基;
各R5各自独立地为氢、C1-C6烷基、-SO2R13、-COR13;
各R9各自独立地为氢、C1-C6烷基、C6-10芳基、5-10元杂芳基,所述芳基、杂芳基可任选地被1-4个选自下组的基团所取代:卤素、羟基、-N(R12)2、硝基、氰基、C1-C6烷基、C1-C6卤代烷基、C1-C6烷氧基、4-8元杂环基;
各R11各自独立地选自C1-C6烷基和C6-10芳基,所述芳基任选地被1-4个选自下组的基团所取代:卤素、C1-6烷基、C1-6烷氧基;
R8、R10、R12各自独立地选自氢、C1-C6烷基;
R13为C1-C6烷基;
Y-为卤离子、甲酸根离子、乙酸根离子、三氟乙酸根离子或氢氧根离子;
m为0、1、2或3;各Q独立地为卤素或C1-C6烷基;
条件是当R0、R4、Rx均为氢且Ry为羟基时,R1不为C1-C6烷氧基。
本发明中,卤素包括氟、氯、溴、碘四个原子,卤离子为氟、氯、溴或碘的一价负离子。
在另一优选例中,R1选自卤素、C1-C4卤代烷基、-N(R5)2、C1-C4烷氧基、C1-C4氘代烷氧基或-O-L-G;其中,L为C1-4亚烷基,所述亚烷基上的1、2或3个氢原子任选地以化学键允许的方式被卤素、羟基、=O所取代;G为卤素、C1-C4卤代烷基、-CN、-N(R9)2、-COOR10、-P+(R11)3Y-、-N+(R11)3Y-、苯基、苯基氧基、4-6元杂环基或6-8元杂芳基;所述苯基、苯基氧基、杂环基和杂芳基未被取代或被1、2或3个选自下组的基团所取代:卤素、羟基、-N(R12)2、硝基、氰基、C1-C6烷基、C1-C6卤代烷基、C1-C6烷氧基、4-8元杂环基。
在另一优选例中,各R5各自独立地为氢或C1-C4烷基。在另一优选例中,各R9各自独立地为氢或C1-C4烷基。在另一优选例中,R10为氢或C1-C4烷基。在另一优选例中,各R11各自独立地为C1-C4烷基或苯基。在另一优选例中,各R12各自独立地为氢或C1-C4烷基。
在另一优选例中,Rx为氢、氟、氯或溴。
在另一优选例中,R0为氢、氟、氯、溴、C1-C4烷基、羟基取代的C1-C4烷基、C1-C4卤代烷基。
在另一优选例中,R4为氢或C1-C4烷基。
在另一优选例中,所述化合物具有如下式(IIa):
其中,各取代基定义与前相同,当R0为氢时,R1不为C1-C6烷氧基。
在另一优选例中,所述化合物具有如下式(IIb):
其中,各取代基定义与权利要求1中相同。
在另一优选例中,各R8为H。
在另一优选例中,R1为C1-C4烷氧基或-O-L-G;其中,L为C1-4亚烷基,所述亚烷基上的1或2个氢原子任选地以化学键允许的方式被氟、氯、溴、羟基、=O所取代;G为氟、氯、溴、C1-C4卤代烷基、-CN、-N(R9)2、-COOR10、-P+(R11)3Y-、-N+(R11)3Y-、苯基、苯基氧基、4-6元杂环基或6-8元杂芳基;所述苯基、苯基氧基、杂环基和杂芳基未被取代或被1、2或3个选自下组的基团所取代:卤素、羟基、-N(R12)2、硝基、氰基、C1-C4烷基、C1-C4卤代烷基、C1-C4烷氧基、4-8元杂环基;
其中,各R5各自独立地为氢或C1-C4烷基;各R9各自独立地为氢或C1-C4烷基;R10为氢或C1-C4烷基;各R11各自独立地为C1-C4烷基或苯基;各R12各自独立地为氢或C1-C4烷基。
在另一优选例中,R1为C1-C4烷氧基或-O-L-G;其中,L为C1-4亚烷基;G为苯基或C1-C4卤代烷基;Ry为羟基或-OP(O)(OH)2;R0为氢或C1-C6烷基;R2和R3各自独立地为C1-C4烷基。
在另一优选例中,所述化合物选自:
本发明的第二方面,提供一种药物组合物,所述药物组合物包含第一方面所述的化合物、其对映异构体、非对应异构体、外消旋混合物、氘代化物及药学上可接受的盐;和
药学上可接受的载体。
本发明的第三方面,提供第一方面所述的化合物、其对映异构体、非对应异构体、外消旋混合物、氘代化物及药学上可接受的盐或者第二方面所述的药物组合物的用途,用于制备线粒体呼吸链复合体I抑制剂;用于制备预防和/或治疗与线粒体呼吸链复合物I活性或表达升高相关的疾病的药物;用于制备预防和/或治疗与线粒体氧化磷酸化作用增强相关的疾病的药物;用于制备预防和/或治疗与细胞衰老相关的疾病的药物;用于制备衰老细胞清除剂;或用于制备预防和/或治疗肿瘤的药物。
在另一优选例中,与线粒体氧化磷酸化作用增强相关的疾病为部分或完全依靠氧化磷酸化代谢途径供应能量的肿瘤。
在另一优选例中,与线粒体氧化磷酸化作用增强相关的疾病为细胞衰老相关的疾病。
在另一优选例中,所述肿瘤选自急性髓性白血病、神经胶质细胞瘤、淋巴瘤、胰腺癌、子宫癌、乳腺癌、非小细胞肺癌、肝细胞癌。
在另一优选例中,所述肿瘤为急性髓性白血病或神经胶质细胞瘤。
在另一优选例中,所述与细胞衰老相关的疾病选自:器官纤维化疾病、慢性肺病、慢性肾病、慢性肝病、骨关节炎、神经退行性疾病、炎症性肠病、动脉粥样硬化、青光眼、白内障、黄斑变性、糖尿病、色斑、少肌症。
在另一优选例中,所述与细胞衰老相关的疾病为器官纤维化疾病,选自肺纤维化、肝纤维化、肾纤维化。
在另一优选例中,所述与细胞衰老相关的疾病为特发性肺纤维化。
在另一优选例中,所述与细胞衰老相关的疾病为肝纤维化。
在另一优选例中,所述与细胞衰老相关的疾病为骨关节炎。
在另一优选例中,所述与细胞衰老相关的疾病为神经退行性疾病,选自阿尔兹海默症、帕金森病、亨廷顿病、肌萎缩性侧索硬化、多发性硬化症。
在另一优选例中,所述与细胞衰老相关的疾病为阿尔兹海默症。
在另一优选例中,所述与细胞衰老相关的疾病为炎症性肠病,选自溃疡性结肠炎、克罗恩病。
本发明还提供通式(I)所示化合物的制备方法,所述方法选自如下路线1或路线2,具体地,取决于五元内酯环的类型。
在下文中,保护基Pg是使得如下情况变得可能的基团:一方面在合成过程中保护反应性官能团,诸如羟基或胺,且在另一方面在合成结束时允许反应性官能团恢复完整。官能团的保护以及去保护的方法将在具体实施例中给出。
路线1适用于R0选自氢、卤素、C1-C6烷基、羟基取代的C1-C6烷基、C1-C6卤代烷基;R4选自氢;其他各取代基定义如前所述的化合物。
路线1:
从购买或合成的苯丙酸衍生物1开始,与手性辅基4-苄基恶唑烷酮2缩合得到化合物3。随后化合物3在大位阻有机强碱的作用下发生羰基α位烷基化反应,得到化合物4。化合物4经还原剂还原消除手性辅基后得到构型单一的化合物5。化合物5在酸催化下发生酯交换反应得到关键中间体单一构型的丁内酯化合物6。随后再利用有机强碱拔氢、在化合物6的酯羰基α位引入取代苄基得到化合物8,化合物8的酚羟基脱保护得到通式(I)的化合物。化合物8再在有机强碱的作用下拔氢进攻亲电试剂得到α位取代的化合物9,化合物9的酚羟基脱保护得到通式(II)的化合物。
路线2适用于R0选自氢,R4选自C1-C6烷基,其他各取代基定义如前所述的化合物。
路线2:
第二合成途径从中间化合物5开始,化合物5的羟基经氧化剂氧化得到相应的醛,随后格氏试剂与醛基反应游离出羟基,得到相应的化合物11。化合物11在酸催化下发生酯交换反应的到关键中间体丁内酯化合物12。随后再利用有机强碱拔氢在化合物12的酯羰基α位引入取代苄基化合物得到化合物13,化合物13的酚羟基脱保护得到通式(III)的化合物。
附图说明
图1示出小鼠在热板实验中的反应时间。
图2示出小鼠关节病理形态图片及OA评分。
图3示出关节软骨免疫组化p16阳性率。
图4示出IPF小鼠给药后体重变化情况。
图5示出小鼠给药后生存率变化情况。
图6示出小鼠肺组织切片Masson染色及病理评分。
图7示出小鼠肺组织衰老标记物p16基因水平。
图8示出小鼠肺组织SASP中IL-6基因水平。
图9示出在水迷宫实验中化合物A4-1a对转基因AD小鼠潜伏期的影响。
图10示出化合物A4-1a对转基因AD小鼠穿越平台数的影响。
图11示出化合物A5对四氯化碳诱导的肝纤维化小鼠肝组织内羟脯氨酸含量的影响。
图12示出化合物A5对肝纤维化小鼠肝脏Masson染色阳性率的影响。
图13示出化合物A5对恶唑酮诱导的肠炎小鼠疾病活动指数的影响。
图14示出化合物A5对恶唑酮诱导的肠炎小鼠结肠病理的影响。
图15示出化合物A4-1a和Arctigenin对小鼠口服30mg/kg后血浆、肝、结肠组织内药物浓度/时间变化曲线。
图16示出化合物A5对小鼠口服30mg/kg后血浆及组织内前药A5(A)和原形A4-1a(B)的药物浓度/时间变化曲线。
具体实施方式
本申请的发明人经过广泛而深入的研究,基于牛蒡子苷元进行结构改造,发现了线粒体呼吸链复合物I抑制活性提高、口服药代动力学性质改善、在动物模型上口服效果显著的一系列化合物,在用于制备药物时具有更好的成药性质和应用潜力。在此基础上,完成了本发明。
术语阐述
在本发明中,除非特别指出,所用术语具有本领域技术人员公知的一般含义。
在本发明中,术语“C1-C6”是指具有1、2、3、4、5或6个碳原子,“C1-C8”是指具有1、2、3、4、5、6、7或8个碳原子,依此类推。“3-8元”是指具有3、4、5、6、7或8个环原子,“5-7元”是指具有5、6或7个环原子,依此类推。
本发明中,“芳环”、“芳基”定义为由特定个数碳原子构成、且遵守Hückel规则的单环和双环体系,包括但不仅限于苯环、萘环。
本发明中,“杂芳环”、“杂芳基”定义为具有特定个数成环原子、且含有1、2、3或4个杂原子(选自N、O、S)、同时遵守Hückel规则的单环和双环体系,包括但不仅限于吡啶、吡咯、咪唑。
本发明中,“芳氧基”定义为芳香性基团上连上氧形成的基团,包括但不限于Ph-O-。
本发明中,“杂环基”定义为由特定个数碳原子构成的饱和或不饱和的非芳族的环状基团,且含有1、2、3或4个杂原子(选自N、O、S),包括但不仅限于吗啉、哌嗪。
本发明中,所述“烷基”和类似的“烷氧基”为具有特定碳原子个数的支链和直链的烃基团和烃氧基团,代表性的例子包括但不仅限于甲基、甲氧基、乙基、乙氧基、正丙基、正丙氧基、异丙基、异丙氧基。
本发明中,所述“卤代烷基”是指具有特定碳原子个数的“烷基”中的氢原子被“卤原子”部分或完全取代所形成的基团。
本发明中,所述“卤原子”包括氟、氯、溴、碘。
本发明中,所述取代为单取代或多取代,所述多取代为二取代、三取代、四取代、或五取代。所述二取代就是指具有两个取代基,依此类推。
本发明所述药学上可接受的盐可以是阴离子与式I化合物上带正电荷的基团形成的盐。合适的阴离子为氯离子、溴离子、碘离子、硫酸根、硝酸根、磷酸根、柠檬酸根、甲基磺酸根、三氟乙酸根、乙酸根、苹果酸根、甲苯磺酸根、酒石酸根、富马酸根、谷氨酸根、葡糖醛酸根、乳酸根、戊二酸根或马来酸根。类似地,可以由阳离子与式I化合物上的带负电荷的基团形成盐。合适的阳离子包括钠离子、钾离子、镁离子、钙离子和铵离子,例如四甲基铵离子。在另一优选例中,“药学上可接受的盐”是指式I化合物同选自下组的酸形成的盐类:氢氟酸、盐酸、氢溴酸、磷酸、乙酸、草酸、硫酸、硝酸、甲磺酸、胺基磺酸、水杨酸、三氟甲磺酸、萘磺酸、马来酸、柠檬酸、醋酸、乳酸、酒石酸、琥珀酸、酢浆草酸、丙酮酸、苹果酸、谷氨酸、对甲苯磺酸、萘磺酸、乙磺酸、萘二磺酸、丙二酸、富马酸、丙酸、草酸、三氟乙酸、硬酯酸、扑酸、羟基马来酸、苯乙酸、苯甲酸、谷氨酸、抗坏血酸、对胺基苯磺酸、2-乙酰氧基苯甲酸和羟乙磺酸等;或者式I化合物与无机碱形成的钠盐、钾盐、钙盐、铝盐或铵盐;或者通式I化合物与有机碱形成的甲胺盐、乙胺盐或乙醇胺盐。
本发明通式I化合物或其药学上可接受的盐是从水或有机溶剂中蒸馏析出、结晶或重结晶而来,化合物中可能包含所使用的溶剂分子。此外,不同的结晶条件可能导致化合物的晶型不同。因此,含有不同化学剂量的结晶溶剂以及所有晶型的通式I所示的化合物或其药学上可接受的盐都在本发明的范围内。本发明中,通式(I)所示化合物用于制备药物时通常为药物组合物的形式,该药物组合物包含通式(I)化合物以及一种或多种药学上可接受的辅料;所述药学上可接受的辅料为药学上可接受的载体、赋形剂、缓释剂、气味剂、香味剂等;所述药物组合物中,通式(I)所示化合物作为活性组分、其重量占药物组合物总重量的0.1~99.9%,其余为药学上可接受的辅料;所述药物组合物可以基于药物制剂领域的惯用工艺制成多种剂型,如片剂、胶囊、溶液、混悬液、气雾剂、干粉等,并可存储于适宜的消毒器具和给药装置中。
本发明中,所述“有效治疗剂量”表示与没有接受该剂量治疗的对象相比,接受该剂量治疗的对象在病变或副作用等得到治愈、改善、有效预防或者其发生率显著降低;此外,它还包括增强正常生理功能的有效剂量。
本发明中,通式(I)所示化合物、其盐及其药物组合物可对人和动物使用;给药途径包括口服、吸入、透皮吸收、注射等;本发明中,优选的给药途径为口服;通式(I)所示化合物、其盐及其药物组合物用于制备药物时;给药剂量和频率应根据医嘱而定。
本发明中,通式(I)所示化合物、其盐及其药物组合物用于预防或治疗癌症和衰老相关疾病时可与其他药物联合使用;所述药物包括但不仅限于抗肿瘤药物、治疗组织纤维化药物、治疗骨关节炎药物。
本发明中,所述“酸”、“碱”、“氧化剂”、“还原剂”均与本领域熟练人员所熟悉的意义相同,本领域熟练技术人员可根据具体反应底物、反应条件的不同进行适当地变化和调整。
以下将以实施例进一步说明本发明。需要特别指出的是,这些实施例只用于举例说明本发明,而不以任何方式限制本发明。实例中的所有参数及其余说明,除另加说明外,都是以质量为依据的。柱层析分离所用填料若未说明均为硅胶。下列实施例中未注明具体条件的实验方法,通常按照常规条件,或按照制造厂商所建议的条件。
除非另行定义,文中所使用的所有专业与科学用语与本领域熟练人员所熟悉的意义相同。此外,任何与所记载内容相似或均等的方法及材料皆可应用于本发明中。文中所述的较佳实施方法与材料仅作示范之用。
缩略语
Bn:苄基;DCM:二氯甲烷;DIPEA:N,N-二异丙基乙胺;DMAP:4-二甲氨基吡啶;DMF:N,N-二甲基甲酰胺;THF:四氢呋喃;LDA:二异丙基氨基锂;NaHMDS:双(三甲基硅基)氨基钠。
实施例1:(3R,4R)-4-(3,4-二甲氧基苄基)-3-(4-羟基-3-甲氧基苄基)-3-甲基二氢呋喃-2(3H)-酮(A4-1a)
(3R,4R)-3-(4-(苄氧基)-3-甲氧基苄基)-4-(3,4-二甲氧基苄基)二氢呋喃-2(3H)-酮(A2-1)的合成
将市售的原料牛蒡子苷元A1-1(3.72g,10.0mmol)溶于60ml丙酮中,再将氯化苄(2.3mL,20mmol),碳酸钾(2.76g,20mmol),碘化钾(63mg,0.5mmol)加入反应体系中,60℃油浴加热搅拌6h.反应完全后,抽滤,滤液减压浓缩,硅胶柱层析[PE:EA=1∶1],得4.32g透明油状物A2-1,产率93.3%。MS m/z:463.2[M+H]+
(3R,4R)-3-(4-(苄氧基)-3-甲氧基苄基)-4-(3,4-二甲氧基苄基)-3-甲基二氢呋喃-2(3H)-酮(A3-1)的合成
将上一步产物A2-1(463mg,1mmol)溶于20ml无水THF中,于-78℃滴加LDA(1mL,2mmol,2mol/L in THF).搅拌40min滴加碘甲烷(186μL,3mmol in 5ml THF),于-78℃下搅拌30min后缓慢升温到室温。反应完全后饱和氯化铵溶液淬灭反应,减压浓缩除去大部分四氢呋喃,剩余物溶于20mL乙酸乙酯,氯化钠溶液洗涤,无水硫酸钠干燥。抽滤,滤液减压浓缩,硅胶柱层析[PE:EA=1∶1],得278mg透明油状物A3-1,产率58.4%。1H NMR(500MHz,Chloroform-d)δ7.46–7.41(m,2H),7.38–7.33(m,2H),7.31–7.27(m,1H),6.81(d,J=2.0Hz,2H),6.77(d,J=2.1Hz,1H),6.71(dd,J=8.2,2.1Hz,1H),6.67(dd,J=8.1,2.0Hz,1H),6.63(d,J=2.0Hz,1H),5.13(s,2H),4.02(dd,J=9.0,7.5Hz,1H),3.88(s,3H),3.87(s,3H),3.86(s,3H),3.62(dd,J=10.2,9.0Hz,1H),2.96(dd,J=13.6,4.8Hz,1H),2.87(d,J=14.0Hz,1H),2.79(d,J=14.1Hz,1H),2.57(m,1H),1.23(s,3H).ESI-MS m/z:477.2[M+H]+。
(3R,4R)-4-(3,4-二甲氧基苄基)-3-(4-羟基-3-甲氧基苄基)-3-甲基二氢呋喃-2(3H)-酮(A4-1a)的合成
将上一步产物A3-1(278mg,0.58mmol)溶于10ml无水甲醇中,加入10%钯碳(30mg),压力为1大气压加氢反应2h完毕。过滤除去催化剂,滤液减压浓缩,硅胶柱层析[PE:EA=1∶1]分离得189mg白色固体A4-1a,产率84%。1H NMR(500MHz,Chloroform-d)δ6.84(d,J=8.0Hz,1H),6.76(d,J=8.2Hz,1H),6.74(d,J=2.1Hz,1H),6.64(dd,J=8.0,2.0Hz,1H),6.60(dd,J=8.1,2.0Hz,1H),6.52(d,J=1.9Hz,1H),3.94(dd,J=9.0,7.8Hz,1H),3.84(s,3H),3.84(s,4H),3.83(s,4H),3.82(d,J=1.3Hz,1H),3.19(d,J=14.0Hz,1H),2.73(dd,J=13.5,4.0Hz,1H),2.62(d,J=14.0Hz,1H),2.58–2.45(m,1H),2.36(dd,J=13.6,11.1Hz,1H),1.28(s,3H).ESI-MS m/z:387.2[M+H]+。
采用本发明实施例1的类似合成方法,以合适的可选起始原料,制备得到表1所示的化合物:
表1化合物及其表征数据
实施例2:(3R,4R)-4-(3,4-二甲氧基苄基)-3-(4-羟基-3-苯乙氧基苄基)二氢呋喃-2(3H)-酮(B9-1a)
(S)-4-苄基-3-(3-(3,4-二甲氧基苯基)丙酰基)-2-噁唑烷酮(B2-1)
将3,4-二甲氧基苯丙酸(B1-1)(10.50g,50.0mmol)溶于300mL无水THF中,于-20℃滴加特戊酰氯(6.0mL,50.0mmol)和三乙胺(21.0mL,150.0mmol),此温度下继续搅拌1h.滴加(S)-4-苄基-2-噁唑烷酮(B1-2)(8.0g,45.0mmol)的THF溶液(100mL),一次性加入无水LiCl(2.10g,50.0mmol),继续搅拌1h后升至室温,再继续搅拌4h.反应液减压浓缩至约50mL,以100mL乙酸乙酯稀释,依次用10%碳酸氢钠、5%硫酸氢钾、饱和氯化钠溶液洗涤,无水硫酸钠干燥。抽滤,滤液减压浓缩,得15.8g白色固体B2-1,不经纯化,可直接用于下步反应。1H NMR(400MHz,Chloroform-d)δ7.35–7.27(m,3H),7.20–7.13(m,2H),6.81(dd,J=3.4,1.7Hz,3H),4.66(ddt,J=9.4,6.9,3.5Hz,1H),4.22–4.03(m,2H),3.88(s,3H),3.85(s,3H),3.36–3.17(m,3H),3.05–2.89(m,2H),2.75(dd,J=13.4,9.5Hz,1H).ESI-MS m/z:370.2[M+H]+。
(S)-4-苄基-3-[(R)-2-乙酸叔丁酯基-3-(3,4-二甲氧基苯基)丙酰基]-2-噁唑烷酮(B3-1)
将上步产物B2-1(15.8g,43mmol)溶于500mL无水THF,于-78℃滴加NaHMDS(32mL,64mmol,2mol/L in THF).搅拌1小时滴加溴乙酸叔丁酯(12.6mL,85mmol),继续在此温度下搅拌5h.饱和氯化铵溶液淬灭反应,减压浓缩除去大部分四氢呋喃,剩余物溶于100mL乙酸乙酯,依次用5%硫酸氢钾和饱和氯化钠溶液洗涤,无水硫酸钠干燥.抽滤,滤液减压浓缩,硅胶柱层析[PE:EA=4∶1],得28.6g白色固体B3-1,两步产率59.2%.1H NMR(400MHz,Chloroform-d)δ7.35–7.31(m,2H),7.27(s,3H),6.87(s,1H),6.76(d,J=1.5Hz,2H),4.60–4.50(m,1H),4.45(ddd,J=10.1,8.4,5.0Hz,1H),4.12(d,J=7.1Hz,1H),4.10–4.06(m,1H),3.97(t,J=8.4Hz,1H),3.89(s,3H),3.85(s,3H),3.35–3.26(m,1H),2.96(dd,J=13.1,6.0Hz,1H),2.85–2.75(m,1H),2.78–2.70(m,1H),2.56(dd,J=13.2,9.3Hz,1H),2.38(dd,J=16.9,4.0Hz,1H),1.46(d,J=1.8Hz,1H),1.40(s,9H).ESI-MS m/z:484.2[M+H]+.
(R)-3-羟甲基-4-(3,4-二甲氧基苯基)-丁酸叔丁酯(B4-1)
将上一步产物B3-1(2.50g,5.2mmol)溶于80mL四氢呋喃中,加入20mL水,分批加入硼氢化钠(0.29g,5.8mmol),室温搅拌2h.减压浓缩除去大部分四氢呋喃,乙酸乙酯稀释,缓慢滴加1mol/L盐酸至无气泡产生.依次用5%硫酸氢钾和饱和氯化钠洗涤,无水硫酸钠干燥.抽滤,滤液减压浓缩,得1.52g无色透明液体B4-1.不经纯化,可直接用于下步反应.1HNMR(400MHz,Chloroform-d)δ6.83–6.69(m,3H),3.87(s,3H),3.85(s,3H),2.65(dd,J=13.6,6.1Hz,1H),2.55(dd,J=14.0,5.9Hz,1H),2.35–2.19(m,3H),2.01(dd,J=14.3,8.7Hz,1H),1.45(s,9H).ESI-MS m/z:311.2[M+H]+
(R)-4-(3,4-二甲氧基苄基)-丁内酯(B5-1)
将上步产物B4-1(1.50g,4.8mmol)溶于20mL甲苯,加入对甲苯磺酸(41.6mg,0.24mmol),于80℃搅拌1小时.减压浓缩除去甲苯.残渣溶于乙酸乙酯,依次用10%碳酸氢钠和饱和氯化钠溶液洗涤,无水硫酸钠干燥,硅胶柱层析[V(石油醚)∶V(乙酸乙酯)=3∶1],得1.14g无色透明油状物B5-1。1H NMR(400MHz,Chloroform-d)δ6.81(d,J=8.1Hz,1H),6.70(dd,J=8.1,2.0Hz,1H),6.66(d,J=2.0Hz,1H),4.34(dd,J=9.1,6.9Hz,1H),4.04(dd,J=9.1,6.0Hz,1H),3.88(s,3H),3.87(s,3H),2.89–2.78(m,1H),2.72(dd,J=7.7,4.1Hz,2H),2.61(dd,J=17.5,8.1Hz,1H),2.29(dd,J=17.5,6.9Hz,1H).ESI-MS m/z:237.1[M+H]+
4-(苄氧基)-3-羟基苯甲醛(B5-2b)的合成
将市售原料B5-2a(1.38g,10mmol)溶于20ml丙酮中,加入碳酸锂(888mg,12mmol),氯化苄(1.37ml,12mmol),碘化钾(83mg,0.5mmol),60℃油浴加热搅拌6h,反应完毕后抽滤除去碳酸锂,滤液减压蒸馏,硅胶柱层析[PE:EA=3∶1]分离得1.82g白色固体B5-2b,产率79.8%。1H NMR(500MHz,Chloroform-d)δ9.84(s,1H),7.46(d,J=2.0Hz,1H),7.43(m,4H),7.41–7.38(m,2H),7.04(d,J=8.2Hz,1H),5.21(s,2H).MS m/z:229.1[M+H]+
4-(苄氧基)-3-((叔丁基二甲基甲硅烷基)氧基)苯甲醛(B5-2c)的合成
上一步产物B5-2b(1.14g,5mmol)溶于20ml二氯甲烷中,冰浴下加N,N-二异丙基乙胺(2.6ml,15mmol),叔丁基二甲基氯硅烷(1.5g,10mmol),冰浴搅拌30min后,恢复至室温搅拌。反应完毕后,减压浓缩反应液,硅胶柱层析[PE:EA=5∶1]分离得1.56g白色固体B5-2c,产率91.2%。1H NMR(500MHz,Chloroform-d)δ9.70(s,1H),7.30-7.34(m,3H),7.29–7.20(m,4H),6.90(d,J=8.3Hz,1H),5.01(s,2H),0.84(s,9H).MS m/z:343.2[M+H]+
(4-(苄氧基)-3-((叔丁基二甲基甲硅烷基)氧基)苯基)甲醇(B5-2d)的合成
上一步产物B5-2c(1.03g,3mmol)溶于10ml四氢呋喃中,温室分批加入硼氢化钠(228mg,6mmol),温室搅拌3h,反应完毕后,硅胶柱层析[PE:EA=3∶1]分离得986mg白色固体B5-2d,产率95.5%。1H NMR(600MHz,Chloroform-d)δ7.35–7.29(m,2H),7.28–7.23(m,2H),7.22–7.19(m,1H),6.78(d,J=1.5Hz,1H),6.76(d,J=1.9Hz,2H),4.93(s,2H),4.44(s,2H),0.85(s,9H).MS m/z:345.2[M+H]+
(2-(苄氧基)-5-(溴甲基)苯氧基)(叔丁基)二甲基硅烷(B5-2e)的合成
三苯基膦(688mg,3mmol)和四溴化碳(996mg,3mmol)溶于5ml二氯甲烷中,室温搅拌5min后,向反应体系中滴加B5-2d(688mg,2mmol)的二氯甲烷(5ml)溶液,温室搅拌4h,反应完毕后,减压浓缩反应液,硅胶柱层析[PE:EA=5∶1]分离得952mg油状物B5-2e,产率78.1%。1H NMR(500MHz,Chloroform-d)δ7.47–7.44(m,2H),7.43–7.38(m,2H),7.38–7.34(m,1H),6.94(d,J=1.4Hz,1H),6.92(d,J=2.2Hz,1H),6.90–6.87(m,1H),5.08(s,2H),4.54(s,2H),1.00(s,9H).MS m/z:407.1[M+H]+
(3R,4R)-3-(4-(苄氧基)-3-((叔丁基二甲基甲硅烷基)氧基)苄基)-4-(3,4-二甲氧基苄基)二氢呋喃-2(3H)-酮(B6-1)的合成
将上步产物B5-1(400.0mg,1.7mmol)的10mL四氢呋喃溶液,于-78℃滴加LDA(1.7mL,3.4mmol,2mol/L in THF).搅拌40min滴加滴加化合物B5-2e(690.2mg,1.7mmol)的5mL四氢呋喃溶液,继续搅拌4h,饱和氯化铵淬灭反应,减压浓缩除去大部分四氢呋喃,剩余物溶于乙酸乙酯,依次用5%硫酸氢钾和饱和氯化钠洗涤,无水硫酸钠干燥后,硅胶柱层析[V(石油醚)∶V(乙酸乙酯)=3∶1],得614mg无色粘稠液体B6-1,收率64.3%.MS m/z:563.3[M+H]+
(3R,4R)-3-(4-(苄氧基)-3-羟基苄基)-4-(3,4-二甲氧基苄基)二氢呋喃-2(3H)-酮(B7-1)的合成
将上步产物B6-1(300.0mg,0.53mmol)溶于5ml盐酸/乙醇(2mol/L)溶液中,于室温下搅拌2h,反应完毕后减压蒸馏除去大部分溶剂,硅胶柱层析[V(石油醚)∶V(乙酸乙酯)=3∶1],得165mg无色粘稠液体B7-1,收率73.6%.MS m/z:449.2[M+H]+
(3R,4R)-3-(4-(苄氧基)-3-苯乙氧基苄基)-4-(3,4-二甲氧基苄基)二氢呋喃-2(3H)-酮(B8-1a)的合成
将上步产物B7-1(165mg,0.37mmol)溶于5mL乙腈中,室温下加碳酸铯(240mg,0.74mmol),市售化合物B7-2a(272mg,1.48mmol)。80℃油浴搅拌2h,反应完毕后抽滤除去碳酸铯,滤液减压蒸馏,硅胶柱层析[V(石油醚)∶V(乙酸乙酯)=3∶1],得195mg油状物B8-1a,收率95.5%.MS m/z:553.2[M+H]+
(3R,4R)-4-(3,4-二甲氧基苄基)-3-(4-羟基-3-苯乙氧基苄基)二氢呋喃-2(3H)-酮(B9-1a)的合成
将上一步产物B8-1a(195mg,0.35mmol)溶于10ml无水甲醇中,加入10%钯碳(20mg),压力为1大气压加氢反应2h完毕。过滤除去催化剂,滤液减压浓缩,硅胶柱层析[PE:EA=2∶1]分离得136mg白色固体B9-1a,产率84.1%。1H NMR(500MHz,Chloroform-d)δ7.33(t,J=7.6Hz,2H),7.29–7.24(m,3H),6.81(dd,J=8.3,2.8Hz,1H),6.73(dd,J=9.5,4.0Hz,1H),6.67(d,J=1.9Hz,1H),6.60(dd,J=8.1,2.0Hz,1H),6.54(dd,J=8.1,2.0Hz,1H),6.47(d,J=2.0Hz,1H),4.22–4.17(m,2H),4.10(dd,J=8.9,7.0Hz,1H),3.87(dd,J=7.5,8.4Hz,1H),3.84(s,3H),3.80(s,3H),3.10(q,J=7.6,6.8Hz,2H),2.90(t,J=4.2Hz,2H),2.64(dd,J=13.1,5.6Hz,1H),2.59–2.42(m,2H).MS m/z:463.2[M+H]+
采用实施例2类似的合成方法,以合适的可选不同的起始原料,制备得到表2所示的化合物:
表2化合物及其表征数据
实施例3:(3R,4R)-4-(3,4-二甲氧基苄基)-3-(4-羟基-3-苯乙氧基苄基)-3-甲基二氢呋喃-2(3H)-酮(B11-1a)
(3R,4R)-3-(4-(苄氧基)-3-苯乙氧基苄基)-4-(3,4-二甲氧基苄基)-3-甲基二氢呋喃-2(3H)-酮(B10-1a)的合成
以化合物B8-1a为原料,合成方法参照化合物A3-1合成。ESI-MS m/z:567.3[M+H]+
(3R,4R)-4-(3,4-二甲氧基苄基)-3-(4-羟基-3-苯乙氧基苄基)-3-甲基二氢呋喃-2(3H)-酮(B11-1a)的合成
以化合物B10-1a为原料,合成方法参照化合物A4-1a的合成。1H NMR(500MHz,Chloroform-d)δ7.34–7.29(m,2H),7.29–7.26(m,3H),6.82(d,J=8.1Hz,1H),6.76(d,J=1.9Hz,1H),6.74–6.71(m,1H),6.66–6.62(m,1H),6.59(dd,J=8.1,2.0Hz,1H),6.51(d,J=2.0Hz,1H),4.25(dd,J=9.0,7.7Hz,1H),4.21(td,J=6.8,1.5Hz,2H),3.94(dd,J=9.0,7.7Hz,1H),,3.83(s,3H),3.82(s,3H),3.17(d,J=14.0Hz,1H),3.09(t,J=6.8Hz,2H),2.72(dd,J=13.5,4.1Hz,1H),2.60(d,J=14.0Hz,1H),2.48-2.54(m,1H),2.40–2.31(m,1H),1.27(s,3H).ESI-MS m/z:477.2[M+H]+
采用实施例3类似的合成方法,以合适的可选起始原料,制备得到表3所示的化合物:
表3化合物及其表征数据
实施例4:(3R,4R)-4-(3,4-二甲氧基苄基)-3-(4-羟基-3-(甲基氨基)苄基)二氢呋喃-2(3H)-酮(B9-3)
4-(苄氧基)-3-硝基苯甲酸甲酯(B5-3b)的合成
市售原料B5-3a(1g,5mmol),氯化苄(687ul,6mmol),碳酸钾(1.38g,10mmol),碘化钾(83mg,0.5mmol)加入30ml丙酮中,60℃加热搅拌5小时。反应完毕后,抽滤除去碳酸钾,滤液减压蒸馏。硅胶柱层析[V(石油醚)∶V(乙酸乙酯)=3∶1],得1.32淡黄色固体B5-3b,收率91.9%。1H NMR(500MHz,Chloroform-d)δ8.52(d,J=2.1Hz,1H),8.17(dd,J=8.8,2.2Hz,1H),7.49–7.32(m,5H),7.16(d,J=8.8Hz,1H),5.31(s,2H),3.93(s,3H).ESI-MS m/z:288.1[M+H]+
(4-(苄氧基)-3-硝基苯基)甲醇(B5-3c)的合成
上一步产物B5-3b(1.04g,4mmol)溶于20mL的无水THF中,冰浴下滴加四氢铝锂溶液(2.5M/L in THF)(2.5ml,10mmol),冰浴搅拌30分钟后缓慢升温到室温反应2小时。反应完毕后冰水淬灭四氢铝锂,乙酸乙酯萃取三次,饱和氯化钠溶液水洗有机层三次,无水硫酸钠干燥有机层,抽滤,滤液减压浓缩,硅胶柱层析[V(石油醚)∶V(乙酸乙酯)=2∶1],得864mg黄色油状物B5-3c,收率83.1%。1H NMR(500MHz,Chloroform-d)δ7.89(d,J=2.2Hz,1H),7.52(dd,J=8.6,2.3Hz,1H),7.50–7.46(m,2H),7.45–7.40(m,2H),7.38–7.33(m,1H),7.13(d,J=8.6Hz,1H),5.27(s,2H),4.71(s,2H).ESI-MS m/z:260.1[M+H]+
1-(苄氧基)-4-(溴甲基)-2-硝基苯(B5-3e)
以B5-3c为原料,参照B5-2e的操作,合成得黄色油状物B5-3e,收率86%。ESI-MSm/z:322.0[M+H]+
(3R,4R)-3-(4-(苄氧基)-3-硝基苄基)-4-(3,4-二甲氧基苄基)二氢呋喃-2(3H)-酮(B6-3)的合成
以B5-3e和B5-1为原料,参照B6-1的操作,合成得淡黄色油状物,收率78%。ESI-MSm/z:478.2[M+H]+
(3R,4R)-3-(3-氨基-4-(苄氧基)苄基)-4-(3,4-二甲氧基苄基)二氢呋喃-2(3H)-酮(B7-3)的合成
上一步产物B6-3(477mg,1mmol),铁粉(280mg,5mmol)溶于10ml甲醇中,加1ml稀盐酸(2M/L)催化,室温搅拌,反应过夜,反应完毕后过滤除去铁粉,滤液减压浓缩,硅胶柱层析[V(石油醚)∶V(乙酸乙酯)=1∶1],得421g淡黄色油状物B7-3,收率94.2%。ESI-MS m/z:448.2[M+H]+
(3R,4R)-3-(4-(苄氧基)-3-(甲基氨基)苄基)-4-(3,4-二甲氧基苄基)二氢呋喃-2(3H)-酮(B8-3)的合成
上一步产物B7-3(223mg,0.5mmol),N,N-二异丙基乙胺(350ul,2mmol),碘甲烷(40ul,0.6mmol)加入5ml二氯甲烷中,室温搅拌5h,反应完毕后,硅胶柱层析[V(石油醚)∶V(乙酸乙酯)=1∶1],得167mg淡黄色油状物B8-3,收率72.6%。ESI-MS m/z:462.2[M+H]+
(3R,4R)-4-(3,4-二甲氧基苄基)-3-(4-羟基-3-(甲基氨基)苄基)二氢呋喃-2(3H)-酮(B9-3)的合成
以B8-3为原料,参照合成A4-1a的操作步骤以及投料比,得到B9-3,收率78.2%。1HNMR(500MHz,Chloroform-d)δ7.10(d,J=8.1Hz,1H),6.79(d,J=8.1Hz,1H),6.59(dd,J=8.1,2.0Hz,1H),6.50(ddd,J=12.0,8.0,2.1Hz,3H),4.18(dd,J=9.2,7.5Hz,1H),3.92–3.87(m,1H),3.87(s,4H),3.83(s,3H),3.17(s,3H),2.88(dd,J=6.0,3.7Hz,2H),2.66(dd,J=13.8,6.7Hz,1H),2.62–2.55(m,2H),2.51–2.43(m,1H).ESI-MS m/z:372.2[M+H]+
采用实施例4类似的合成方法,以合适的可选起始原料,制备得到表4所示的化合物。
表4化合物及其表征数据
实施例5:(3R,4R)-4-(3,4-二甲氧基苄基)-3-(4-羟基-3-甲氧基苄基)-5-甲基二氢呋喃-2(3H)-酮(C9-1a)
3-(3,4-二甲氧基苄基)-4-氧代丁酸叔丁酯(C5-1)的合成
将中间体B4-1(620mg,2mmol)溶于10mL的二氯甲烷中,加入戴斯马丁试剂(932mg,2.2mmol),室温搅拌1小时,反应完成后,硫代硫酸钠水溶液淬灭反应,二氯甲烷萃取3次,水洗有机层3次,无水硫酸钠干燥有机层,抽滤,滤液减压浓缩,硅胶柱层析[V(石油醚):V(乙酸乙酯)=4∶1],得587mg白色油状物C5-1,收率96.5%。ESI-MS m/z:309.2[M+H]+。
3-(3,4-二甲氧基苄基)-4-羟基戊酸叔丁酯(C6-1a)的合成
将中间体C5-1(587mg,1.9mmol)溶于超干四氢呋喃中,于冰浴下滴加甲基溴化镁溶液(1M/L in THF)(2mL,2mmol),冰浴搅拌30分钟后缓慢升温到室温反应2小时。反应完毕后冰水淬灭甲基溴化镁溶液,乙酸乙酯萃取三次,饱和氯化钠溶液水洗有机层三次,无水硫酸钠干燥有机层,抽滤,滤液减压浓缩,硅胶柱层析[V(石油醚)∶V(乙酸乙酯)=4∶1],得592mg透明油状物C6-1a,收率91.1%。ESI-MS m/z:325.2[M+H]+。
4-(3,4-二甲氧基苄基)-5-甲基二氢呋喃-2(3H)-酮(C7-1a)的合成
以C6-1a为原料,参照合成B5-1的操作步骤以及投料比,得到C7-1a,收率82.2%。ESI-MS m/z:251.1[M+H]+。
3-(4-(苄氧基)-3-甲氧基苄基)-4-(3,4-二甲氧基苄基)-5-甲基二氢呋喃-2(3H)-酮(C8-1)
以C7-1a和7为原料,参照合成B6-1的操作步骤以及投料比,得到C8-1,收率56.3%。ESI-MS m/z:477.2[M+H]+。
4-(3,4-二甲氧基苄基)-3-(4-羟基-3-甲氧基苄基)-5-甲基二氢呋喃-2(3H)-酮(C9-1a)
以C8-1为原料,参照合成A4-1a的操作步骤以及投料比,得到C9-1a,收率87.4%。1H NMR(400MHz,Chloroform-d)δ6.77(d,J=8.0Hz,1H),6.71(d,J=8.1Hz,1H),6.57(d,J=1.9Hz,0H),6.51(dt,J=7.9,1.8Hz,1H),6.48(d,J=1.9Hz,1H),6.41(d,J=2.0Hz,1H),3.86(d,J=3.4Hz,3H),3.83(d,J=4.1Hz,2H),3.78–3.69(m,5H),2.96(dd,J=14.2,5.9Hz,0H),2.90–2.82(m,1H),2.70–2.59(m,2H),2.61–2.46(m,1H),1.33(d,J=6.6Hz,2H),1.07(d,J=6.2Hz,1H).ESI-MS m/z:387.2[M+H]+。
采用实施例5类似的合成方法,以合适的可选起始原料,制备得到表5所示的化合物。
表5化合物及其表征数据
实施例6:4-(((3R,4R)-4-(3,4-二甲氧基苄基)-3-甲基-2-氧代四氢呋喃-3-基)甲基)-2-甲氧基苯基磷酸二氢酯(A5)
将化合物A4-1a(0.1mmol)溶于超干二氯甲烷中,冰浴下加入三乙胺(0.5mmol),搅拌均匀后加入三氯氧磷(0.2mmol),冰浴下反应30分钟。冰水淬灭反应,二氯甲烷萃取反应液,无水硫酸镁干燥,过滤,减压蒸馏,半制备液相纯化得化合物A5。1H NMR(500MHz,DMSO-d6)δ7.21(d,J=8.2Hz,1H),6.92(d,J=2.0Hz,1H),6.86(d,J=8.2Hz,1H),6.75(dd,J=8.3,2.0Hz,1H),6.71(d,J=2.0Hz,1H),6.67(dd,J=8.0,2.1Hz,1H),4.02(t,J=9.4Hz,1H),3.94(t,J=8.1Hz,1H),3.74(s,3H),3.72(s,3H),3.71(s,3H),2.99(d,J=13.6Hz,1H),2.75(d,J=13.6Hz,1H),2.69–2.62(m,1H),2.48–2.37(m,1H),2.00(dt,J=15.9,6.9Hz,2H),1.22(s,3H).MS(ESI,m/z):465.2[M-1]-。
采用实施例6类似的合成方法,以合适的可选起始原料,制备得到表6所示的化合物。
实施例7药理活性和药效评价
1、化合物对线粒体呼吸复合物I(Complex I)抑制活性评价
1.1评价方法
线粒体提取于小鼠心脏组织。心脏组织加入200-250mL的solution A(0.22Mmannitol(甘露醇),0.07M sucrose(蔗糖),0.02M HEPES,2mM Tris-HCl,1mM EDTA,pH7.2,0.4%BSA),组织剪碎,然后用solution A再清洗3次去除血液和结缔组织。采用玻璃匀浆器,对组织进行匀浆,30次左右。悬液于3000g 1.5分钟,取上清留用,沉淀solution A加入蛋白酶抑制剂再次重悬后重新离心,收集上清,两次上清混合进行下一步。上清于17500g离心2.5分钟,弃上清,沉淀采用solution A加入蛋白酶抑制剂再次重悬后,再次17500g离心4.5分钟。Solution B(2.5mM potassium phosphate,5mM MgCl2 pH 7.2)再次重悬后进行反复冻融制得后续用于检测的线粒体复合物溶液。
Complex I的NADH活性测定,2.5mL反应液配制:50mM HEPES,5mM MgCl2 pH 7.5加入30μg上述过程中的线粒体蛋白。然后加入需要检测的化合物平衡5分钟,随后分装至每一个孔,最后快速加入NADH(50μM),于340nM每30sec读数一次,一共进行15分钟反应。计算:不同化合物中NADH反应速率计算,然后计算抑制率(化合物反应速率/对照反应速率*100),最后再计算化合物的IC50值。
1.2评价结果
表6化合物对Complex I的抑制活性
化合物 | Complex I IC<sub>50</sub>(nM) | 化合物 | Complex I IC<sub>50</sub>(nM) |
A4-1a | 507 | B9-1u | 564 |
A4-1b | 1271 | B9-1v | 34 |
A4-1c | 185 | B9-1x | 650 |
A4-1e | 473 | B11-1a | 646 |
B9-1a | 54 | B11-1b | 668 |
B9-1d | 696 | B11-1e | 1374 |
B9-1p | 465 | B11-1f | 420 |
B9-1q | 64 | B11-1h | 13220 |
B9-1r | 316 |
由评价结果可见,本发明化合物具有微摩尔至纳摩尔水平的Complex I抑制活性,能用于制备治疗线粒体呼吸链复合物I功能异常所致疾病的药物。。
2、化合物对人急性髓细胞白血病细胞(OCI-AML3)活力影响的评价
2.1实验方法
OCI-AML3细胞为悬浮细胞,培养于RPIM1640+10%FBS+1%PS培养液中,37℃,5%CO2。OCI-AML3按照20000个细胞/孔接种于96孔板中,同时加入不同浓度的化合物(40μM为最高浓度,按照1/4进行稀释,一共7个浓度),共同孵育3天后,每孔加入10μl的CCK8试剂,孵育2小时后,通过酶标仪检测OD450,然后计算化合物对细胞活力的影响,计算IC50值。
2.2评价结果
表7代表化合物对OCI-AML3细胞的抑制活性
化合物 | OCI-AML3 IC<sub>50</sub>(nM) | 化合物 | OCI-AML3 IC<sub>50</sub>(nM) |
A4-1a | 81 | B9-1e | 274 |
A4-1d | 169 | B11-1b | 47 |
A4-1i | 91 | B11-1c | 289 |
B9-1d | 602 | Arctigenin | 589 |
由评价结果可见,本发明化合物具有良好的抑制OCI-AML3细胞活性的作用,能用于制备治疗急性髓性白血病的药物。
3、化合物对人神经母细胞瘤细胞(NB-1)活力影响评价
3.1实验方法
NB-1细胞为悬浮细胞,培养于RPIM1640+10%FBS+1%PS培养液中,37℃,5%CO2。NB-1按照20000个细胞/孔接种于96孔板中,同时加入不同浓度的化合物(40μM为最高浓度,按照1/4进行稀释,一共7个浓度),共同孵育3天后,每孔加入10μL的CCK8试剂,孵育2小时后,通过酶标仪检测OD450,然后计算化合物对细胞活力的影响,计算IC50值。
3.2评价结果
表8代表化合物对NB-1细胞的抑制活性
化合物 | NB-1IC<sub>50</sub>(nM) | 化合物 | NB-1IC<sub>50</sub>(nM) |
A4-1a | 424 | A4-1d | 546 |
A4-1i | 433 | B11-1b | 626 |
B9-1e | 175 | B11-1c | 446 |
Arctigenin | 2380 |
由评价结果可见,本发明化合物具有良好的抑制NB-1细胞活性的作用,能用于制备治疗神经胶质细胞瘤的药物。
4、化合物对衰老的人纤维母细胞(WI-38)和小鼠骨样细胞(MLO-Y4)的活力影响评价
4.1实验方法
4.1.1化合物对WI-38正常细胞和衰老细胞选择性实验:
WI-38细胞培养于DMEM(高糖,4.5g/L)培养液中(加入10%FBS,1%PS)。
化合物对WI-38衰老细胞活力影响的实验检测步骤如下:WI-38细胞按照20000个/孔接种于96孔板中,隔夜后每孔均加入200nM的阿霉素孵育3天,更换成正常培养液继续孵育1天,再更换成200nM的阿霉素孵育3天,即可成功诱导WI-38细胞衰老;随后加入不同浓度的化合物(40μM为最高浓度,按照1/4进行稀释,一共7个浓度),共同孵育3天后,每孔加入MTT(5mg/ml)10μl,继续孵育4小时后,吸取培养液后每孔加入DMSO(150μl),振荡孵育15分钟后,采用酶标仪检测OD490,然后计算化合物对细胞活力的影响,计算IC50值。
4.1.2化合物对MLO-Y4正常细胞和衰老细胞选择性实验:
MOL-Y4细胞培养于MEM培养液中(加入10%FBS,1%PS)。
化合物对MOL-Y4衰老细胞活力影响的实验检测步骤如下:MOL-Y4细胞按照20000个/孔接种于96孔板中,隔夜后每孔均加入100nM的阿霉素孵育3天,更换成正常培养液继续孵育1天,再更换成100nM的阿霉素孵育3天,即可成功诱导MOL-Y4细胞衰老;随后加入不同浓度的化合物(40μM为最高浓度,按照1/4进行稀释,一共7个浓度),共同孵育3天后,每孔加入MTT(5mg/ml)10μl,继续孵育4小时后,吸取培养液后每孔加入DMSO(150μl),振荡孵育15分钟后,采用酶标仪检测OD490,然后计算化合物对细胞活力的影响,计算IC50值。
4.2评价结果
表9代表化合物对衰老细胞活力的抑制作用
化合物 | WI-38IC<sub>50</sub>(nM) | MOL-Y4 IC<sub>50</sub>(nM) |
A4-1a | 38 | 40 |
A4-1e | 1000 | 150 |
ABT263 | 5600 | 235 |
注:BCL-2抑制剂ABT263为阳性对照。
由评价结果可见,本发明化合物可有效地抑制衰老细胞的活力。由于衰老细胞不具有复制能力,因此细胞活力的降低即代表被药物诱导凋亡,也就是被清除。本发明化合物清除衰老细胞的作用优于现有的衰老细胞清除剂ABT263,能用于制备治疗衰老相关疾病的药物。
5、化合物对骨关节炎模型小鼠的药效评价
5.1实验原理和方法
原理:
小鼠膝关节的内侧半月板韧带切除术导致小鼠的膝关节半月板不稳定,从而诱导小鼠骨性关节炎。骨性关节炎的一个重要临床特征为关节疼痛、关节肿胀和活动受限,所以增加骨性关节炎小鼠的疼痛敏感性被认为对骨性关节炎具有治疗作用。因此,本实验对C57小鼠进行内侧半月板韧带切除术,诱导小鼠骨性关节炎,然后手术侧膝关节皮下注射药物持续八周,然后通过热板实验检测骨性关节炎小鼠的疼痛敏感性,小鼠膝关节的番红固绿染色实验,进而评价化合物对骨性关节炎的治疗作用。
方法:
1)采用内侧半月板韧带切除术导致内侧半月板不稳定(destabilization of themedical meniscus,DMM)的骨性关节炎模型小鼠。
A,8周龄的C57雄性小鼠麻醉后,75%乙醇将小鼠右侧后肢膝关节处消毒,然后用剪刀再右侧膝关节处将皮肤剪开2cm的切口。随后采用钝性分离右侧膝关节内侧处肌肉和滑膜组织,然后将髌骨采用钝器向外侧移位,暴露关节腔,在手术显微镜下钝性分离关节腔内脂肪垫,暴露膝关节内侧半月板韧带,然后通过手术刀片将内侧半月板韧带切断,能够明显感觉内侧半月板游离(可以滑动)。随后将髌骨复位,依次缝合肌肉和皮肤。手术后腹腔注射给予青霉素(100mg/kg/day)3天,预防细菌感染。
B,手术后当天小鼠苏醒后给药组给与化合物A4-1a(2mM,50μL/只),其他组给与溶剂(生理盐水)。其后隔天给药一次,持续8周。
2)最后一次注射后,第二天进行热板实验,检测小鼠的疼痛敏感性。实验方法如下,小鼠于实验环境适应30分钟,将小鼠置于52℃的热板上,记录小鼠初次出现如舔足底、跳动等行为的时间,每只小鼠进行3次实验,然后进行统计学分析。
3)热板实验结束后,采用二氧化碳窒息致死,随后取小鼠右侧后肢膝关节(进行手术的关节)固定于多聚甲醛中,随后进行脱钙,然后进行石蜡切片,并对小鼠膝关节组织进行番红固绿染色或p16免疫染色,在显微镜下观察膝关节软骨组织形态,进行骨性关节炎评分(OA Score)和p16阳性面积测定,并进行统计学分析。
5.2评价结果
图1示出小鼠在热板实验中的反应时间;图2示出小鼠关节病理形态图片及OA评分;图3示出关节软骨免疫组化p16阳性率。
由评价结果可见,本发明化合物A4-1a能显著减少热板实验中骨关节炎小鼠的反应时间,表明有助于小鼠运动能力的恢复。在病理评价中,A4-1a能恢复受损关节软骨表面的光滑度和完整性,降低小鼠关节组织病理评分,降低软骨中衰老标记物p16的表达,表明化合物A4-1a可有效清除损伤诱导的衰老细胞、改善骨关节病理形态。
6、化合物对博来霉素诱导的特发性肺纤维化(IPF)小鼠的药效评价
6.1实验方法
实验动物:雄性C57小鼠,24-28g/只,70只。
博来霉素诱导肺纤维化模型及给药:65只C57小鼠,博来霉素按照2U/kg,麻醉后经口咽部吸入给药进行IPF造模,于给药前和给药后第5天测定每只小鼠对应的体重,选取体重有明显下降的小鼠作为造模成功的标准,选取20只成功造模的小鼠分为2组(分别:溶剂组——给予溶剂,A4-1a-30组——口服给药给予A4-1a 30mg/kg/day,A4-1a-10组——口服给药给予A4-1a 10mg/kg/day),另外选取5只C57小鼠作为正常小鼠对照。于第5天开始给药,给药14天。每天记录小鼠的体重和生存率。
小鼠脏器处理:给药后第15天,小鼠麻醉后称重,处死小鼠,去小鼠肺组织,称重,小鼠肺指数的计算方法:小鼠肺组织重量/小鼠体重*1000;取肺组织中间1/3部分组织取出后固定于4%多聚甲醛中,用于后续石蜡切片及Masson染色。
小鼠肺组织Masson染色:按照常规方法将小鼠肺组织进行石蜡包埋后,切片进行masson染色。具体程序如下:切片脱蜡后,苏木素染色2分钟,蒸馏水2-3秒,分化液2-3秒,蒸馏水2-3秒,返蓝液2-3秒,蒸馏水2-4分钟,品红染色6分钟,蒸馏水2-3秒,磷钼酸2-3秒,苯胺蓝2分钟,1%乙酸2-3秒,100%乙醇2分钟,重复100%乙醇2分钟,二甲苯2分钟,重复二甲苯2分钟,中性树胶封片。
6.2评价结果
图4示出IPF小鼠给药后体重变化情况;图5示出小鼠给药后生存率变化情况;图6示出小鼠肺组织切片Masson染色及病理评分;图7示出小鼠肺组织衰老标记物p16基因水平;图8示出小鼠肺组织SASP中IL-6基因水平。
由评价结果可见,本发明化合物A4-1a能显著减缓IPF小鼠的体重降低,提高小鼠生存率,降低肺组织切片纤维化程度(Masson染色评分)、降低肺组织内衰老标记物p16水平和衰老相关的分泌表型IL-6,表明化合物对改善或治疗衰老相关疾病IPF具有十分显著的效果。
7、化合物A4-1a对阿尔兹海默症(AD)小鼠的药效评价
7.1实验原理与方法
本发明中采用APP/PS1转基因的阿尔茨海默症(AD)模型小鼠。这类转基因小鼠高表达嵌和鼠/人的瑞典突变APP(Mo/HuAPP695swe)和人源的删除了第9个外显子的早老素1蛋白(presenilin,PS1-dE9),这类转基因小鼠会在6个月的时候出现较明显的Aβ沉积并且会在7个月的时候出现空间记忆力的损害。因此,本发明采用六个月大小的APP/PS1转基因的AD小鼠,灌胃给药(A4-1a,30mg/kg/day)三个月后通过Morris水迷宫实验检测A4-1a对转基因小鼠的记忆力损伤情况,以此类型老鼠的阴性小鼠为对照组,评价A4-1a对阿尔茨海默病的治疗作用。
1)APP/PS1双转基因AD模型小鼠进行繁殖。对子代小鼠的转基因型鉴定,通过采用对小鼠剪尾,然后PCR鉴定小鼠的APP/PS1的基因序列。以非转基因小鼠作为实验中的阴性对照小鼠。小鼠在标准条件下饲养(12/12小时明暗循环,足够水和食物,22℃的恒温,60%的湿度)。
2)AD模型小鼠给药:在小鼠6月大小时,20只转基因小鼠被随机分为2组(转基因溶剂组,转基因A4-1a-30mg/kg/day剂量组),10只非转基因小鼠作为阴性对照组。A4-1a溶解于百分之二的吐温80中,灌胃给药90天,然后开始行为学实验检测(Morris水迷宫实验)。
3)小鼠每天进行三次训练,持续8天的时间。在训练小鼠面向池壁置于水中,60秒钟时间去寻找平台位置,小鼠在平台上停留15秒钟时间以帮助它记忆平台位置。在此期间,记录小鼠找到平台的时间即潜伏期。在第9天,在三次训练之后,小鼠进行平台寻找实验,潜于水面下的平台被撤除,然后让小鼠在水池中持续90秒钟去寻找平台,记录小鼠穿越平台次数作为其记忆力的评价指标,次数越多表明其记忆力越好。所有的动物实验操作都严格遵守《实验动物管理条例》。
7.2评价结果
如图9和图10所示,转基因小鼠(T-V)的潜伏期明显长于非转基因小鼠(NT-V),而穿越平台次数明显少于非转基因小鼠,表明转基因小鼠的记忆力出现明显损伤,表明其AD模型正确。口服给予A4-1a 30mg/kg/day的转基因小鼠(T-A4-1a-30)潜伏期明显短于溶剂处理的转基因小鼠,而穿越平台次数明显多于溶剂处理的转基因小鼠,表明A4-1a能够逆转转基因小鼠出现的记忆力损伤表现。这些结果表明A4-1a能够起到很好治疗阿尔茨海默病效果。
8、化合物A5对四氯化碳诱导的肝纤维化小鼠的药效评价
8.1实验方法
实验动物:雄性C57小鼠,8周龄,40只。
建模及给药:400uL的四氯化碳(CCl4)加入3.6mL的橄榄油中混匀然后按照0.1mL/20g进行腹腔注射,每周2次,持续六周。六周后30只小鼠分为3组,每组10只,分别采用灌胃方式给予生理盐水,A5剂量1mg/kg和A5剂量3mg/kg。另外,10只未进行诱导的小鼠给予生理盐水作为对照组。持续给药3周后小鼠处死,取肝脏进行称重后,进行固定及包埋,剩余肝脏组织冻存,进行羟脯氨酸含量检测。
小鼠肝组织Masson染色:按照常规方法将小鼠肝组织进行石蜡包埋后,切片进行masson染色。具体程序如下:切片脱蜡后,苏木素染色2分钟,蒸馏水2-3秒,分化液2-3秒,蒸馏水2-3秒,返蓝液2-3秒,蒸馏水2-4分钟,品红染色6分钟,蒸馏水2-3秒,磷钼酸2-3秒,苯胺蓝2分钟,1%乙酸2-3秒,100%乙醇2分钟,重复100%乙醇2分钟,二甲苯2分钟,重复二甲苯2分钟,中性树胶封片。
小鼠肝组织羟脯氨酸含量检测:采用羟脯氨酸检测试剂盒进行(南京建成生物工程研究所),简单介绍如下:称取肝脏组织40mg,加入碱裂解液0.5mL,95℃水解20分钟,然后加入酸碱度指示剂5μL,混匀,再加入调pH甲液0.5ml,混匀后呈红色,在缓慢加入调pH乙液至红色消失呈黄绿色。随后加入去离子水5mL混匀,然后加入活性炭20mg混匀后,3500转/分钟离心10分钟,取上清用于羟脯氨酸测定。按照试剂盒说明分别加入反应试剂一后,反应10分钟,再加入反应试剂二反应5分钟,最后加入反应试剂3后于60℃反应15分钟,然后于3500转/分钟离心15分钟,上清采用酶标仪于波长550nm测定吸光值。然后计算每100mg的肝脏组织中的羟脯氨酸含量。
8.2评价结果
如图11所示,CCl4诱导并给予溶剂的小鼠肝脏中所含羟脯氨酸(HYP)高于正常对照组小鼠,具有统计学意义。而化合物A5灌胃给与1mg/kg/day和3mg/kg/day均能够明显地降低CCl4诱导引起的羟脯氨酸含量增高,具有统计学意义。
如图12所示,CCl4诱导的小鼠肝脏组织Masson染色阳性率,即肝纤维化面积相对正常组小鼠明显增加,具有统计学意义。而化合物A5灌胃给与1mg/kg/day和3mg/kg/day均能够明显地降低小鼠的肝纤维化程度,具有统计学意义。
以上结果表明,化合物A5对于改善或治疗肝纤维化具有较好的效果。
9、化合物A5对恶唑酮诱导的炎症性肠病小鼠的药效评价
9.1实验方法
实验动物:雄性C57小鼠,8周龄,30只。
建模及给药:3%的恶唑酮(Oxazolone)溶解于溶剂(丙酮:橄榄油,1:4)中,小鼠麻醉后,将小鼠肩部毛发剔除,然后滴150uL质量分数为3%的Oxazolone。在处理后的第8天,1%的Oxazolone溶解于溶剂(乙醇:灭菌水,1:1),小鼠麻醉后,进行直肠给予1%的Oxazolone 150uL进行造模。造模小鼠分为两组,每组10只,一组给予化合物A5灌胃1mg/kg/day,一组给予生理盐水,另外一组不进行造模的10只小鼠作为对照组。从造模当天开始,每天记录小鼠体重,直肠给药后第三天收集小鼠的粪便,观察其粪便松软程度,是否有出血。然后小鼠处死,取远端3cm左右的小鼠结肠进行固定。
小鼠肠炎疾病活动指数评分:根据小鼠体重减少程度(0:正常;1:1–5%;2:6–10%;3:11–18%;4:>18%),粪便松软程度(0:正常;2:软;4:腹泻),粪便出血程度(0:正常;2:隐血;4:血便),然后各分数相加后除以三。
小鼠结肠组织伊红-苏木精染色:将小鼠结肠组织固定后,进行石蜡切片,然后进行伊红-苏木精染色。小鼠结肠炎症指数计算方法:根据小鼠结肠粘膜完整性(0:正常;1:粘膜损伤;2:粘膜下损伤;3:肌肉损伤),炎症细胞浸润程度(0:正常;1:大量炎症细胞粘膜层浸润;2:炎症细胞浸润到粘膜下层;3:炎症细胞浸润透入肌层),结肠的水肿程度(0:正常;1:轻度水肿;2中度水肿;3中度水肿)。
9.2评价结果
如图13所示,Oxazolone诱导的肠炎模型小鼠的疾病活动指数明显高于正常组,而灌胃给予化合物A5(1mg/kg/day)能够显著地降低肠炎疾病活动指数。
如图14所示,Oxazolone诱导的肠炎模型小鼠的结肠病理评分明显高于正常对照组小鼠,而灌胃给予A5(1mg/kg/day)能够明显地减少结肠病理评分。
以上结果表明化合物A5对治疗或缓解炎症性肠病变具有明显效果。
实施例8药代动力学评价
1、化合物A4-1a和牛蒡子苷元(Arctigenin)的口服药代动力学评价
1.1实验方法
30mg/kg的Arctigenin和化合物A4-1a分别口服给药给予禁食过夜的ICR小鼠(雄性,n=3/时间点)。于给药后2小时喂食小鼠。分别于给药前及给药后1h、2h、4h、8h采集样,用肝素钠和磷酸二(4-硝基苯基)酯(BNPP)预处理的离心管中收集血液。离心后在4℃下以11,000rpm的转速离心5分钟,获得血浆并将其储存在-80℃下。接下来,将100mL甲醇/乙腈(1:1,v/v)添加到10mL血浆样品中,将其沉淀,涡旋振荡1分钟,离心(11,000rpm)5分钟。取20mL上清液和20mL甲醇/乙腈(1:1,v/v)的混合物通过LC-MS/MS分析化合物的浓度。肝脏组织并保存在-80℃直至分析。除去内含物后,结肠用含有BNPP的冷盐水快速洗涤,并保存在-80℃直至分析。分析方法:组织样品中加入10倍重量的MeOH/ACN(1:1,v/v)后用匀浆机在50Hz条件下匀浆120s后获得匀浆。将匀浆离心(11000rpm)5分钟并收集上清液。然后将20μL上清液重新溶解于20μL ACN/H2O(1:1,v/v)中后在LC-MS/MS中分析化合物的浓度。
1.2评价结果
图15示出化合物A4-1a和Arctigenin对小鼠口服30mg/kg后血浆、肝、结肠组织内药物浓度/时间变化曲线。
由评价结果可见,相比于Arctigenin,结构改造所得化合物A4-1a口服相同剂量后血浆和组织药物浓度显著提高,表明口服药代动力学性质获得了意想不到的改善。
2、化合物A4-1a的磷酸酯前药A5的口服药代动力学评价
2.1实验方法
口服给药化合物A5(30mg/kg)给予禁食过夜的ICR小鼠(雄性,n=3/时间点)。于给药后2小时喂食小鼠。分别于给药前及给药后1h、2h、4h、8h采集样,用肝素钠和磷酸二(4-硝基苯基)酯(BNPP)预处理的离心管中收集血液。离心后在4℃下以11,000rpm的转速离心5分钟,获得血浆并将其储存在-80℃下。接下来,将100mL甲醇/乙腈(1:1,v/v)添加到10mL血浆样品中,将其沉淀,涡旋振荡1分钟,离心(11,000rpm)5分钟。取20mL上清液和20mL甲醇/乙腈(1:1,v/v)的混合物通过LC-MS/MS分析化合物A5以及A4-1a的浓度。心脏(血排空)、肝脏、肺组织并保存在-80℃直至分析除去内含物后,十二指肠和结肠用含有BNPP的冷盐水快速洗涤,并保存在-80℃直至分析。分析方法:组织样品中加入10倍重量的MeOH/ACN(1:1,v/v)后用匀浆机在50Hz条件下匀浆120s后获得匀浆。将匀浆离心(11000rpm)5分钟并收集上清液。然后将20μL上清液重新溶解于20μL ACN/H2O(1:1,v/v)中后在LC-MS/MS中分析化合物A5以及A4-1a的浓度。
2.2评价结果
图16示出化合物A5对小鼠口服30mg/kg后血浆及组织内前药A5(A)和原形A4-1a(B)的药物浓度/时间变化曲线。
由评价结果可见,磷酸酯前药A5口服后在体内能高效地代谢出原型化合物A4-1a,在血浆及各组织内均有较好的药物浓度,因此在制备预防或治疗本发明所述疾病的药物中同样具有潜在的应用价值。
总之,本发明基于牛蒡苷元(Arctigenin)进行结构改造得到通式I化合物并产生了意想不到的效果,或者提高了Complex I活性,或者提高了抑制肿瘤细胞活性,或者提高了清除衰老细胞活性,或者改善了口服药代动力学性质,或者在疾病动物模型中表现出了十分显著的药效,因此在预防和/或治疗与线粒体呼吸链复合物I活性或表达升高、或者线粒体氧化磷酸化作用增强相关的疾病中具有很好的应用潜力。
Claims (10)
1.一种式I所示的化合物、其对映异构体、非对应异构体、外消旋混合物、氘代化物及药学上可接受的盐,
其中,
Rx选自氢、羟基、卤素;
R0选自氢、卤素、C1-C6烷基、羟基取代的C1-C6烷基、C1-C6卤代烷基;
R1选自卤素、C1-C6卤代烷基、-N(R5)2、C1-C6烷氧基、C1-C6氘代烷氧基或-O-L-G;其中,L为C1-6亚烷基,所述亚烷基的氢原子任选地以化学键允许的方式和数量被卤素、羟基、=O所取代;G为卤素、C1-C6卤代烷基、-CN、-N(R9)2、-COOR10、-P+(R11)3Y-、-N+(R11)3Y-、C6-10芳基、C6-10芳氧基、4-8元杂环基或5-10元杂芳基;所述芳基、芳氧基、杂环基和杂芳基未被取代或被1、2、3或4个选自下组的基团所取代:卤素、羟基、-N(R12)2、硝基、氰基、C1-C6烷基、C1-C6卤代烷基、C1-C6烷氧基、4-8元杂环基;
R2和R3各自独立地为C1-C6烷基、C1-C6卤代烷基,或R2和R3连接起来并连同相连接的C形成未取代或取代的5-8元杂环基,所述取代是指被选自下组的一个或多个取代基取代:卤素、C1-C6烷基;
R4为氢或C1-C6烷基;
各R5各自独立地为氢、C1-C6烷基、-SO2R13、-COR13;
各R9各自独立地为氢、C1-C6烷基、C6-10芳基、5-10元杂芳基,所述芳基、杂芳基可任选地被1-4个选自下组的基团所取代:卤素、羟基、-N(R12)2、硝基、氰基、C1-C6烷基、C1-C6卤代烷基、C1-C6烷氧基、4-8元杂环基;
各R11各自独立地选自C1-C6烷基和C6-10芳基,所述芳基任选地被1-4个选自下组的基团所取代:卤素、C1-6烷基、C1-6烷氧基;
R8、R10、R12各自独立地选自氢、C1-C6烷基;
R13为C1-C6烷基;
Y-为卤离子、甲酸根离子、乙酸根离子、三氟乙酸根离子或氢氧根离子;
m为0、1、2或3;各Q独立地为卤素或C1-C6烷基;
条件是当R0、R4、Rx均为氢且Ry为羟基时,R1不为C1-C6烷氧基。
4.如权利要求1所述化合物,其特征在于,R1选自卤素、C1-C4卤代烷基、-N(R5)2、C1-C4烷氧基、C1-C4氘代烷氧基或-O-L-G;其中,L为C1-4亚烷基,所述亚烷基上的1、2或3个氢原子以化学键允许的方式被卤素、羟基、=O所取代;G为卤素、C1-C4卤代烷基、-CN、-N(R9)2、-COOR10、-P+(R11)3Y-、-N+(R11)3Y-、苯基、苯基氧基、4-6元杂环基或6-8元杂芳基;所述苯基、苯基氧基、杂环基和杂芳基未被取代或被1、2或3个选自下组的基团所取代:卤素、羟基、-N(R12)2、硝基、氰基、C1-C6烷基、C1-C6卤代烷基、C1-C6烷氧基、4-8元杂环基;
其中,各R5各自独立地为氢或C1-C4烷基;各R9各自独立地为氢或C1-C4烷基;R10为氢或C1-C4烷基;各R11各自独立地为C1-C4烷基或苯基;各R12各自独立地为氢或C1-C4烷基。
5.如权利要求1所述化合物,其特征在于,Ry为羟基或-OP(O)(OH)2;
R0为氢或C1-C6烷基;
R2和R3各自独立地为C1-C4烷基;
R1为C1-C4烷氧基或-O-L-G;其中,L为C1-4亚烷基;G为苯基或C1-C4卤代烷基。
7.一种药物组合物,其特征在于,所述药物组合物包含权利要求1所述的化合物、其对映异构体、非对应异构体、外消旋混合物、氘代化物及药学上可接受的盐;和
药学上可接受的载体。
8.如权利要求1所述的化合物、其对映异构体、非对应异构体、外消旋混合物、氘代化物及药学上可接受的盐或者权利要求7所述的药物组合物的用途,其特征在于,
用于制备线粒体呼吸链复合体I抑制剂;
用于制备预防和/或治疗与线粒体呼吸链复合物I活性或表达升高相关的疾病的药物;
用于制备预防和/或治疗与线粒体氧化磷酸化作用增强相关的疾病的药物;
用于制备预防和/或治疗与细胞衰老相关的疾病的药物;
用于制备衰老细胞清除剂;或
用于制备预防和/或治疗肿瘤的药物。
9.如权利要求8所述的用途,其特征在于,所述肿瘤选自:急性髓性白血病、神经胶质细胞瘤、淋巴瘤、胰腺癌、子宫癌、乳腺癌、非小细胞肺癌、肝细胞癌。
10.如权利要求8所述的用途,其特征在于,所述与细胞衰老相关的疾病选自:器官纤维化疾病、慢性肺病、慢性肾病、慢性肝病、骨关节炎、神经退行性疾病、炎症性肠病、动脉粥样硬化、青光眼、白内障、黄斑变性、糖尿病、色斑、少肌症。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110419576.1A CN115215821A (zh) | 2021-04-19 | 2021-04-19 | 木脂素衍生物、其制备方法及用途 |
PCT/CN2022/083003 WO2022222686A1 (zh) | 2021-04-19 | 2022-03-25 | 木脂素衍生物、其制备方法及用途 |
CN202280021312.3A CN117440947A (zh) | 2021-04-19 | 2022-03-25 | 木脂素衍生物、其制备方法及用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110419576.1A CN115215821A (zh) | 2021-04-19 | 2021-04-19 | 木脂素衍生物、其制备方法及用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115215821A true CN115215821A (zh) | 2022-10-21 |
Family
ID=83605859
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110419576.1A Pending CN115215821A (zh) | 2021-04-19 | 2021-04-19 | 木脂素衍生物、其制备方法及用途 |
CN202280021312.3A Pending CN117440947A (zh) | 2021-04-19 | 2022-03-25 | 木脂素衍生物、其制备方法及用途 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280021312.3A Pending CN117440947A (zh) | 2021-04-19 | 2022-03-25 | 木脂素衍生物、其制备方法及用途 |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN115215821A (zh) |
WO (1) | WO2022222686A1 (zh) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102342929A (zh) * | 2010-08-02 | 2012-02-08 | 中国科学院上海药物研究所 | 牛蒡子苷元及其衍生物在制备药物中的用途 |
CN102451178A (zh) * | 2010-10-29 | 2012-05-16 | 中国科学院上海药物研究所 | 二氢呋喃-2-酮类化合物在制备抗糖尿病及糖脂代谢药物中的用途 |
US9675538B2 (en) * | 2012-03-30 | 2017-06-13 | Rohto Pharmaceutical Co., Ltd. | Anti-aging agent containing arctigenin derivative |
CN103417554B (zh) * | 2012-05-22 | 2018-04-27 | 中国科学院上海药物研究所 | 一种抗肿瘤的药物组合物及其应用 |
-
2021
- 2021-04-19 CN CN202110419576.1A patent/CN115215821A/zh active Pending
-
2022
- 2022-03-25 CN CN202280021312.3A patent/CN117440947A/zh active Pending
- 2022-03-25 WO PCT/CN2022/083003 patent/WO2022222686A1/zh active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN117440947A (zh) | 2024-01-23 |
WO2022222686A1 (zh) | 2022-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110291065B (zh) | 一种新的异二氢吲哚衍生物、其药物组合物及应用 | |
WO2020001420A1 (zh) | 一类细胞坏死抑制剂及其制备方法和用途 | |
KR20150132146A (ko) | 헤모글로빈 조정을 위한 화합물 및 이의 용도 | |
TW201247636A (en) | Novel 3-hydroxyisothiazole 1-oxide derivatives | |
UA72611C2 (uk) | Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази | |
PT86459B (pt) | Processo para a preparacao de derivados de cumarano substituidos naposicao 3 | |
CN108864127B (zh) | 一种含有不同烷基链长的氧桥双环庚烯磺酰胺类化合物及其制备方法与应用 | |
WO2019223732A1 (zh) | 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用 | |
CA3130371A1 (en) | Novel thyromimetics | |
US8871802B2 (en) | Naphthoquinones for disease therapies | |
WO2021249533A1 (zh) | 雌激素受体调节剂化合物及其用途 | |
CN112047944A (zh) | 一种选择性抑制激酶化合物及其用途 | |
CN107074800A (zh) | 经取代的双环杂芳基化合物作为rxr促效剂 | |
CN111285841A (zh) | 用于治疗癌症、神经障碍和纤维化病症的脂类呋喃、吡咯和噻吩化合物 | |
CN111182896A (zh) | 脂肪性肝病的治疗剂以及肥胖症的治疗剂 | |
CN115215821A (zh) | 木脂素衍生物、其制备方法及用途 | |
TW201625614A (zh) | 新穎雜環衍生物 | |
KR20070007149A (ko) | 이미다조피리딘 화합물 | |
KR20120122705A (ko) | 혈관 신생 억제 및 항산화 효과를 가지는 이미다졸계 알칼로이드 유도체 및 이의 제조방법 | |
CN115427407B (zh) | 一种新型n-杂环bet溴结构域抑制剂、其制备方法及医药用途 | |
EP4273150A1 (en) | Tricyclic compound, and preparation method therefor and medical use thereof | |
WO2022171088A1 (zh) | 吡唑并[3,4-d]嘧啶-3-酮衍生物 | |
WO2017173960A1 (zh) | 一类抑制丙肝病毒的大环状杂环化合物及其制备和用途 | |
CN112979675B (zh) | 一种小分子含硫杂环化合物 | |
JP7278273B2 (ja) | アクチビン受容体様キナーゼの阻害剤としての置換ピロロピリジン |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |